WO2005112667A1 - Health food - Google Patents

Health food Download PDF

Info

Publication number
WO2005112667A1
WO2005112667A1 PCT/JP2004/006849 JP2004006849W WO2005112667A1 WO 2005112667 A1 WO2005112667 A1 WO 2005112667A1 JP 2004006849 W JP2004006849 W JP 2004006849W WO 2005112667 A1 WO2005112667 A1 WO 2005112667A1
Authority
WO
WIPO (PCT)
Prior art keywords
harmful
acid
excretion
health food
chelating agent
Prior art date
Application number
PCT/JP2004/006849
Other languages
French (fr)
Japanese (ja)
Inventor
Takashi Omori
Original Assignee
Takashi Omori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Omori filed Critical Takashi Omori
Priority to PCT/JP2004/006849 priority Critical patent/WO2005112667A1/en
Priority to JP2006519161A priority patent/JPWO2005112667A1/en
Publication of WO2005112667A1 publication Critical patent/WO2005112667A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents

Definitions

  • the present invention relates to a health food that excretes harmful heavy metals or harmful minerals accumulated in a human or animal body.
  • JP-A-2003-61631 discloses powdered beverages and foods containing citrate and an amino acid as main components.
  • An object of the present invention is to provide an intake of each nutrient for improving athletic performance and a compounding ratio that makes use of the characteristics of the nutrient.
  • Palin, leucine, anoreginin, isoleucine, methionine, threonine, lysine and the like, and the vitamins are vitamin 8, vitamin B1, B2, B3, B6, B12, niacin, folic acid and the like.
  • a mixture of a powdery isolated soybean protein and a powder containing anthocyanin is added to an organic compound such as citric acid, tartaric acid, and malic acid.
  • an organic compound such as citric acid, tartaric acid, and malic acid.
  • Japanese Patent Application Publication No. 9-502258 discloses a novel clinical marker, a therapeutic agent and a method of use in renal lithiasis.
  • a complex compound of metal ions such as cadmium, lead, strontium, and arsenic, including heavy metal contamination of the environment, is formed, and its concentration is reduced. Let Therefore, it is also used for treating heavy metal poisoning in the human or animal body.
  • dichenic acid cyclic ester, cunic acid is used as a starting material.
  • an automated lead assay disclosed in Japanese Patent Publication No. 9-507026 discloses a method of mixing a sample suspected of containing lead with a disulphide enzyme inhibited in the presence of lead, a substrate that reacts with the enzyme, and a fluorescer. To form an Atsey solution, to which a lead recovery agent, , A lead chelating agent such as sodium citrate is added. By measuring the amount of the enzyme-substrate reaction product, the amount of lead in the sample can be measured indirectly.
  • Patent Document 1 JP 2003-61631 A
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2002-230
  • Patent Document 3 Japanese Patent Publication No. 9-502258
  • Patent Document 4 Japanese Patent Publication No. 9-507026
  • an object of the present invention is to provide a health food that efficiently excretes harmful heavy metals or harmful minerals accumulated in the human or animal body from the human or animal body.
  • the present invention according to claim 1 comprises an essential chelating agent or a chelating agent-derived material, methylsulfonylmethane, citric acid, and L-cystine;
  • the essential chelating agent or the chelating agent-derived material is formed in a solid state or a fluid state, and the essential chelating agent or the chelating agent-derived material is ingested into a human body or an animal body, whereby the human body or the animal body has The harmful heavy metal or harmful mineral is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or harmful mineral is excreted from the human or animal body. It is a healthy food.
  • the invention of claim 2 provides malic acid, L-parin, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cystine, L-methionine, ethylenediamine, EDTA, polylipoic acid, and flavonoids.
  • At least one of a compound, tartaric acid, gnoreconic acid, and alginic acid is added, and the added chelating agent is formed into a solid or fluid, and the added chelating agent is added to the human or animal body.
  • the harmful heavy metal or harmful mineral in the human or animal body is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or the harmful mineral becomes 2.
  • the present invention according to claim 3 is the health food according to claim 2, wherein the essential chelating agent or the chelating agent-derived material, and the added chelating agent power is 0.001 to 35.0% by weight.
  • vitamin B1 vitamin B2, vitamin B6, vitamin
  • B12 comprising at least one kind of folic acid, wherein the saccharide is dalcosamine.
  • the sixth aspect of the present invention is the health food according to the first or second aspect, wherein Noji is added.
  • the present invention according to claim 7 is the health food according to claim 1 or 2, which is formed into a powder, a granule, a tablet, or a paste, or the powder or the granule is contained in a capsule.
  • the present invention according to claim 8 is characterized in that as a flavoring agent, a fruit juice extract, bontan extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, a sweetener, acesulfame K, erythritol, oligo Saccharides, mannose, xylitole, catabolized saccharides, tea components such as green tea, oolong tea, banaba tea, Tochu tea, Tei Kannon tea, noto, tom tea, amatiyaru tea, makomo tea, kelp tea, and yogurt flavor, vitamin C 3.
  • a flavoring agent a fruit juice extract, bontan extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, a sweetener, acesulfame K, erythritol, oligo Saccharides, mannose, xylitole, catabolized saccharides, tea
  • the harmful heavy metal is composed of at least one of Cd, Hg, Pb, and Cr
  • the harmful mineral is composed of at least one of Al, Be, and As. It is a health food described in 1 or 2.
  • the essential chelating agent or the chelating agent-derived material is methylsulfonylmethane, citrate, L-cystine, and the essential chelating agent or the chelating agent-derived material is solid.
  • the essential chelating agent or chelating agent-inducing substance when the essential chelating agent or chelating agent-inducing substance is ingested into the human or animal body by being formed in a fluid form, it blocks harmful heavy metals or harmful minerals in the human or animal body to chelate harmful heavy metals. Substances or toxic minerals are formed, and harmful heavy metals or harmful minerals Excreted from the body.
  • the mixing ratio of the essential chelating agent or chelating agent-derived material and the added chelating agent is selected. , Can be adjusted.
  • the health food is added with at least one of vitamins and carbohydrates.
  • vascular cells are reinforced, which is useful for preventing arteriosclerosis.
  • the vitamin comprises at least one of vitamin B1, vitamin B2, vitamin B6, vitamin B12, and folic acid, and the carbohydrate is dalcosamine.
  • vascular cells are reinforced, which is useful for preventing arteriosclerosis.
  • health food is added with Noji.
  • the health food is formed into solid powders, granules, or tablets, or the powders and granules are contained in a capsule. It is also formed into a paste that is in fluid form.
  • a flavoring agent a botan extract, a lychee extract, an apple juice, an orange juice, a yuzu extract, a peach flavor, a plum flavor, a sweetness agent, acesulfame K as a sweetener, Erythritol, oligosaccharides, mannose, xylitole, isomerized saccharides, green tea, oolong tea, banaba tea, junchu tea, iron guanyin tea, pigeon tea, amachiazul tea, makomo tea, kelp tea, yogurt flavor, vitamins One or more types of C are added.
  • a composition that does not remove the flavoring agent only for the purpose of excluding harmful heavy metals or harmful minerals is within the scope of the present invention.
  • Taste is important because administration over a medium to long term is preferable for the effectiveness of the excretion effect.
  • a flavoring agent is added to improve the taste.
  • the health food has various tastes according to the type and the amount of the flavoring agent added, the taste is improved, and the health food is easy to be used for medium- to long-term administration.
  • the harmful heavy metal is at least one of Cd, Hg, Pb, and Cr
  • the harmful mineral is at least one of Al, Be, and As.
  • Hazardous heavy metals are blocked by an essential chelating agent or chelating agent-derived material or an added chelating agent to form a toxic heavy metal chelating compound
  • harmful minerals are an essential chelating agent or a chelating agent-derived material, or an added chelating agent.
  • To form a toxic mineral chelate compound As a result, one or more of Cd, Hg, Pb, and Cr are used as chelating compounds of harmful heavy metals, and one or more of Al, Be, and As are used as chelating compounds of harmful minerals. Or it is excreted in the body of the animal.
  • a subject collects urine in the morning in the morning before the ingestion of the health food of the present invention in a cleaning plastic cup, measures the total excretion (including nocturnal urine), stores the partial urine in a PFA (fluororesin processed) container, and then ingests In the morning, in the morning and evening, the health food of the present invention was ingested according to the method of ingestion, and in the early morning of the next day, the same amount as the previous day's urine was collected and the total excreted amount was measured (including nocturnal urine). Store in FA (fluororesin processing) container.
  • FA fluororesin processing
  • Blanks should not contain biological samples.
  • Example 11-11 harmful minerals in urine and excretion of minerals in urine before and after ingestion of health foods are summarized below.
  • a normality test was performed for each data, and when the data followed a normal distribution, a paired t-test was performed. When each data did not follow the normal distribution, a Wilcoxon signed rank sum test was performed.
  • Example 1 The components of the health food in Example 1 are as follows:
  • Methylsulfonylmethane (42.5 mg), citric acid (50 mg), L-cystine (2.5 mg), malic acid (50) mg, L-parin (125) mg, L-mouth isine (125) mg , L-isoleucine (125) mg, phycocyanin (25) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (0) mg, ethylenediamine (0) mg, EDTA (0) mg , Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg, and vitamin Bl (0) mg, vitamin B2 (0) mg, Vitamin B6 (0) mg, Vitamin B12 (0) zg, folic acid (0) zg, (0) mg gnorecosamine, (0) mg noni, and the flavoring agent is grapefruit juice (50) mg, and oligosaccharide (1500) mg.
  • Example 1 as shown in Table 1, the average value of arsenic (As) was 10.22 (zg / hr) and 21.46 ( ⁇ g / hr), as shown in Figure 2. 2. One-time increase in excretion was observed. In addition, a significant difference test of these results demonstrated that there was a significant difference in p-value of 0.016 (p-0.05) in the t-test and an increase in arsenic excretion after ingestion. Similarly, when examining each harmful mineral, as shown in Table 1, the average value of mercury (Hg) was 0.106 ( ⁇ / 1 ⁇ ) and 0.160, as shown in Fig. 3. ( ⁇ / 1 ⁇ ) and about 1.5 times the amount of excretion An increase was observed.
  • Hg mercury
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • the mg and flavoring agents consist of (50) mg of orange juice and (1500) mg of oligosaccharides.
  • Example 2 the harmful mineral excretions at bedtime before and after ingestion of health foods are summarized.As shown in Table 3, the average value of arsenic (As) was 8.6 (/ ig / hr) to 18.57 ( / g / hr) and about a 2.1-fold increase in excretion. In addition, a significant difference test of the results showed that there was an increase in arsenic excretion after ingestion with a significant difference in p value of 0.0096 (p ⁇ 0.05) in the t test. Similarly, when considering also the harmful minerals, as shown in Table 3, the mercury (Hg), Mean value 0. 083 ( ⁇ 71 1 month at about a et 0. 152 (zg / hr) 1. 83 A two-fold increase in excretion was observed.
  • the excretion was increased by about 1.42 times to 00 ( ⁇ g / hr).
  • Urinary mineral excretion per hour during bedtime ig / hr.
  • Example 3 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized. As shown in Table 5, the average value of arsenic (As) was 10 ⁇ 09 (/ ig / hr) as shown in Table 5. The excretion was increased by about 2.1 times to 19 ⁇ 60 (/ ig / hr). The Wilcoxon test also demonstrated a significant difference in arsenic excretion after ingestion.
  • the average value of cadmium (Cd) was 0.040 (zg / hr), and 0.070 ( ⁇ / 111 and mercury (13 ⁇ 4) increased about 1.8 times as much as that of mercury (13 ⁇ 4).
  • the average value of lead (Pb) increased from 0.054 (zg / hr) to 0.086 ( ⁇ g / hr), a 1.6-fold increase.
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 4 the amount of harmful mineral excretion during bedtime before and after ingestion of the health food was summarized. As shown in Table 7, the average value of arsenic (As) was 13.76 (/ ig / hr). The excretion was increased by about 1.4-fold to 19 ⁇ 34 (zg / hr). In addition, a significant difference test of the results showed that the Wilcoxon test showed a significant difference in the increase in arsenic excretion after ingestion with a significant difference. Similarly, when each harmful mineral is examined, as shown in Table 7, the average value of mercury (Hg) is 0.099 ( ⁇ / 111 mosquitoes, etc., 0.135 ( ⁇ / 111 and 1.36%).
  • the excretion was increased by 79 ( ⁇ g / hr), about 1.6 times.
  • urinary mineral excretion was increased to 9.773 (xgZhr) and 10.811 ( ⁇ g / hr) as the average value for calcium (Ca). Although there was a change of about 1.1 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 5 the harmful mineral excretions at bedtime before and after ingesting the health food were summarized.
  • Table 9 the average value of arsenic (As) was 8.20 (zg / hr) to 17.13 (zg / hr) and about a 2.1-fold increase in excretion.
  • a significant difference test of this result shows that the Wilcoxon test showed a significant difference in arsenic excretion after ingestion. And it was proved.
  • the average value of mercury (Hg) was 0.107 ( ⁇ / 1 ⁇ ), 0.169 ( ⁇ / 1 ⁇ ) A five-fold increase in excretion was noted.
  • the excretion of cadmium (Cd) is about 1.5 times the average from 0.050 (zg / hr) to 0.078 ( ⁇ / 111 and mercury (13 ⁇ 4)).
  • the average value of lead (Pb) was 0.059 (zg / hr), 0.082 ( ⁇ g / hr), and about 1.3 times higher. Increased excretion was observed.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • vitamin Bl (3) mg, vitamin B2 (3) mg, vitamin B6 (3) mg, vitamin B12 (3) / ig, folic acid (20) / ig, darcosamine (10) mg, and noni (10 ) mg and flavoring agents consist of (50) mg of grape juice and (1500) mg of oligosaccharides.
  • Table 6 summarizes the total excretion of harmful minerals during bedtime before and after ingesting health foods for Example 6, and as shown in Table 11, the average value of arsenic (As) was 10 ⁇ 27 (/ ig / hr). 16 The excretion was increased by about 1.6 times, 65 (/ 1 ⁇ / 1 ⁇ ). In addition, a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference from the p-value of 0.032 (p ⁇ 0.05) in the t-test. Similarly, when examining each harmful mineral, as shown in Table 11, the average value of mercury (Hg) was 0.098 ( ⁇ ⁇ / ⁇ ) and 0.139 ( ⁇ g / hr). 1. A four-fold increase in excretion was observed.
  • the average excretion of lead (Pb) was 0.072 ( ⁇ g / hr) and 0.093 ( ⁇ g / hr). .
  • the urinary mineral excretion amount was 8.362 (/ ig / hr) and the average value was 10.689 (/ ig / hr) for calcium (Ca).
  • the increase in calories resulted in a change of about 1.3 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 7 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized.
  • the arsenic (As) was 11.81 (/ ig / hr) was 19.5 2 ⁇ / ⁇ ), an increase of about 1.7 times in excretion.
  • a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference of p-value of 0.010 (p-0.05) in the t-test.
  • mercury (Hg) The excretion was increased by about 193 (zg / hr), about 1.7 times.
  • urinary mineral excretion increased in calcium (Ca) by an average of 7.711 (/ ig / hr) to 11.586 (/ ig / hr). About 1.5 times However, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • citric acid 100) mg, L-cystine (2.5) mg, linoleic acid (100) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg, phycocyanin (2.5) mg, phytic acid (0) mg, L-cystine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, ⁇ —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added.
  • Example 8 the amount of harmful mineral excretion during bedtime before and after ingestion of health food was summarized.
  • the average value of arsenic (As) was 10 ⁇ 69 (/ ig / hr) An increase in excretion of about 20.24 (and about 1.9-fold was observed.
  • a significant difference test showed that the t-test showed a significant difference in p-value of 0.016 (p-0.05) after ingestion of arsenic excretion.
  • the average value of mercury (Hg) was 0.107 ( The mosquitoes were 0.182 (/ ig / hr), an increase of the excretion of about 1.7 times.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 9 the harmful mineral excretions at bedtime before and after ingesting the health food were summarized.
  • the arsenic (As) level of 8.708 (zg / hr) The amount of excretion increased by about 1.9 times, which was 16.697 ( ⁇ / ⁇ ).
  • this result It was demonstrated that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test.
  • the average of mercury (Hg) was 0.088 ⁇ / 1 ⁇ ) and 0.139 ( ⁇ / 1 ⁇ ). 1. 6-fold increase in non-excretion was observed.
  • the average value of cadmium (Cd) is 0.038 (zg / hr), the power is 0.064 (zg / hr), and the amount of excretion is about 1.7 times that of mercury (Hg). Increased.
  • the average excretion of lead (Pb) was 0.149 (zg / hrW 0.179 ( ⁇ g / hr)), an increase of about 1.2 times.
  • urinary mineral excretion was increased to 8.833 (g / hr) for calcium (Ca) at an average value of 7 ⁇ 281 g / hr. Although there was a change of about 1.2 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 10 the amount of harmful mineral excretion at bedtime before and after ingestion of health food was summarized. As shown in Table 19, the average value of arsenic (As) was 10.54 (/ ig / hr) The excretion was increased by about 1.9-fold to 19.70 (/ 1 ⁇ / 1 ⁇ ). In addition, a significant difference test of the results proved that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test.
  • urinary mineral excretion shows that calcium (Ca) has an average of 9.267 (/ ig / hr) and 10.041 (/ ig / hr). Although the increase in calories resulted in a change of about 1.1-fold, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
  • the urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
  • Example 11 The components of the health food in Example 11 were: Methylsulfonylmethane (50) mg, citric acid (45) mg, L-cystine (5) mg, malic acid (0) mg, L_palin (0) mg, L-mouth isine (0) mg, L-isoleucine (0) mg, phycocyanin (0) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, alginic acid (0) mg, vitamin B l (10) mg, vitamin B2 ( 10) mg, vitamin B6 (10) mg, vitamin B12 (5) ⁇ g, folic acid (25) zg, (0) mg gnorecosamine, and (0) mg noni.
  • Example 11 the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized.
  • Table 21 the average value of arsenic (As) was 9.31 (zg / hr).
  • the excretion increased by about 1.3-fold from 11.90 ( ⁇ / ⁇ 11, and a significant difference test was performed.
  • the t-test (p ⁇ 0.05) showed a significant difference in the intake. It was later proved to be capable of increasing arsenic excretion.
  • mercury (Hg) an increase in excretion of about 1.3 times was observed.
  • the average value of cadmium (Cd) is 0.043 ( ⁇ g / hr) and the power is 0.064 ( ⁇ g / hr), which is about 1.5 times higher than that of mercury (Hg). Increased excretion was observed.
  • the average excretion was 0.073 g / hr, and the excretion was about 1.3 times as high as 0.092 ( ⁇ g / hr). .
  • the urinary mineral excretion amount was 9.019 (/ ig / hr) and 9.443 (/ ig / hr) in average for calcium (Ca). Increase the number of calories by about 1.04 times However, when a test similar to arsenic was performed on this result, a significant difference was not obtained in the t test. (T-test, ⁇ ⁇ 0. 05 for 0.11)
  • Intake of the health food of the present invention in daily life and in the absence of the health food increase the urinary excretion of harmful minerals with a statistically significant difference and maintain secondary health. It is considered to be a useful food for promotion.
  • Harmful heavy metals or harmful minerals that accumulate and deposit in the human body or animal body by foods and food additives and induce various health disorders and diseases are efficiently excreted from the human body or animal body, Prevent the induction of health disorders and diseases. Furthermore, it can be widely used in fields that require improvement and healing.
  • FIG. 1 is a comparison graph of total urinary lead (Pb) excretion before and after ingestion of health food.
  • FIG. 2 is a comparison graph of total urinary arsenic (As) excretion before and after ingestion of health food.
  • FIG. 3 is a comparison graph of total urinary mercury (Hg) excretion before and after intake of health food.
  • FIG. 4 is a comparison graph of the total excretion of cadmium (Cd) in urine before and after intake of health food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A health food which enables harmful heavy metals or harmful minerals accumulated in the human or animal body to be efficiently excreted from the body. The health food contains: additive chelating agents comprising methylsulfonylmethane, citric acid, and L-cystine as essential chelating agents or chelating-agent-inducing substances and further including at least one of malic acid, L-valine, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cysteine, L-methionine, ethylenediamine, EDTA, α-lipoic acid, flavonoid compounds, tartaric acid, gluconic acid, and alginic acid; at least one of vitamins and glucides; and a flavor. When the health food is taken by a human or animal, chelate compounds of harmful heavy metals or of harmful minerals are formed and the harmful heavy metals or harmful minerals are excreted from the human or animal body.

Description

明 細 書  Specification
健康食品  healthy food
技術分野  Technical field
[0001] 本発明は、人体又は動物の体内に蓄積されている有害重金属又は有害ミネラルを ***させる健康食品に関するものである。  The present invention relates to a health food that excretes harmful heavy metals or harmful minerals accumulated in a human or animal body.
背景技術  Background art
[0002] 従来、例えば特開 2003— 61631号公報において、クェン酸とアミノ酸を主成分と した粉末飲料及び食品が開示されている。本発明の目的は、運動パフォーマンスを 向上させるための各栄養素の目安となる摂取量とその栄養素の特徴を生かす配合 比を提供することで、具体的な成分は、クェン酸の他に、アミノ酸は、パリン、ロイシン 、ァノレギニン、イソロイシン、メチォニン、スレオニン、リジン等であり、ビタミンは、ビタミ ン八、ビタミン Bl、 B2、 B3、 B6、 B12、ナイァシン、葉酸等である。  Conventionally, for example, JP-A-2003-61631 discloses powdered beverages and foods containing citrate and an amino acid as main components. An object of the present invention is to provide an intake of each nutrient for improving athletic performance and a compounding ratio that makes use of the characteristics of the nutrient. , Palin, leucine, anoreginin, isoleucine, methionine, threonine, lysine and the like, and the vitamins are vitamin 8, vitamin B1, B2, B3, B6, B12, niacin, folic acid and the like.
さらに、例えば特開 2002-230号公報に示される飲食用粉末組成物において、粉 末状分離大豆蛋白質とアントシァニンを含有する粉末物とを配合したものに、クェン 酸、酒石酸、リンゴ酸等の有機酸を含有させて、色調を改善し、粉末組成物に対する 有機酸の適正な重量比を選ぶことで、良好な食味を有する粉末組成物が得られる。  Further, for example, in a food and drink powder composition disclosed in Japanese Patent Application Laid-Open No. 2002-230, a mixture of a powdery isolated soybean protein and a powder containing anthocyanin is added to an organic compound such as citric acid, tartaric acid, and malic acid. By adding an acid to improve the color tone and selecting an appropriate weight ratio of the organic acid to the powder composition, a powder composition having good taste can be obtained.
[0003] さらに、例えば特表平 9—502258号公報において、腎結石症における新規な臨床 マーカー、治療剤および使用方法が開示されている。本発明では、新規の化合物が 金属イオンを錯体化する性質を利用して、環境の重金属汚染を含む、カドミウム、鉛 、ストロンチウム、砒素などの金属イオンの錯化合物を形成させ、その濃度を減少さ せる。従って、人体又は動物の体内における重金属中毒の治療にも用いられる。新 規の化合物であるジクェン酸環状エステルの化学合成におレ、て、クェン酸等を出発 物質としている。しかし、本発明では、当該化合物の投与前後における、個々の有害 金属イオンの減少の動態についての具体的な開示はない。  [0003] Further, for example, Japanese Patent Application Publication No. 9-502258 discloses a novel clinical marker, a therapeutic agent and a method of use in renal lithiasis. In the present invention, utilizing the property of the novel compound to complex metal ions, a complex compound of metal ions such as cadmium, lead, strontium, and arsenic, including heavy metal contamination of the environment, is formed, and its concentration is reduced. Let Therefore, it is also used for treating heavy metal poisoning in the human or animal body. In the chemical synthesis of a new compound, dichenic acid cyclic ester, cunic acid is used as a starting material. However, in the present invention, there is no specific disclosure about the kinetics of reduction of individual harmful metal ions before and after administration of the compound.
さらに、例えば特表平 9-507026号公報に示される自動鉛アツセィは、鉛を含む 疑いのある試料を、鉛の存在下で阻害されるジスルフイド酵素、この酵素と反応する 基質、及びフルォレッサーと混合してアツセィ溶液を形成し、これに鉛回収剤、好適 にはクェン酸ナトリウム等の鉛キレート剤をカ卩える。酵素一基質反応生成物の量を測 定することで、試料中の鉛の量を間接的に測定し得るとする。 Furthermore, for example, an automated lead assay disclosed in Japanese Patent Publication No. 9-507026 discloses a method of mixing a sample suspected of containing lead with a disulphide enzyme inhibited in the presence of lead, a substrate that reacts with the enzyme, and a fluorescer. To form an Atsey solution, to which a lead recovery agent, , A lead chelating agent such as sodium citrate is added. By measuring the amount of the enzyme-substrate reaction product, the amount of lead in the sample can be measured indirectly.
特許文献 1 :特開 2003 - 61631号公報  Patent Document 1: JP 2003-61631 A
特許文献 2:特開 2002 - 230号公報  Patent Document 2: Japanese Patent Application Laid-Open No. 2002-230
特許文献 3:特表平 9 - 502258号公報  Patent Document 3: Japanese Patent Publication No. 9-502258
特許文献 4:特表平 9 - 507026号公報  Patent Document 4: Japanese Patent Publication No. 9-507026
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0004] そこで、本発明は、人体又は動物の体内に蓄積された有害重金属又は有害ミネラ ルを人体又は動物の体内から効率的に***させる健康食品を提供することを目的と する。 [0004] Therefore, an object of the present invention is to provide a health food that efficiently excretes harmful heavy metals or harmful minerals accumulated in the human or animal body from the human or animal body.
課題を解決するための手段  Means for solving the problem
[0005] 請求項 1の本発明は、必須キレート剤又はキレート剤誘導材料物質であるメチルス ルフォニルメタン、クェン酸、 L—シスチンから成り、 [0005] The present invention according to claim 1 comprises an essential chelating agent or a chelating agent-derived material, methylsulfonylmethane, citric acid, and L-cystine;
前記必須キレート剤又はキレート剤誘導材料物質は固体状又は流体状に形成され、 前記必須キレート剤又はキレート剤誘導材料物質が人体又は動物の体内に摂取さ れることにより、前記人体又は動物の体内の有害重金属又は有害ミネラルを封鎖して 前記有害重金属のキレートイヒ合物又は前記有害ミネラルのキレートィヒ合物が形成さ れ、前記有害重金属又は有害ミネラルが前記人体又は動物の体内から***されるこ とを特徴とする健康食品である。  The essential chelating agent or the chelating agent-derived material is formed in a solid state or a fluid state, and the essential chelating agent or the chelating agent-derived material is ingested into a human body or an animal body, whereby the human body or the animal body has The harmful heavy metal or harmful mineral is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or harmful mineral is excreted from the human or animal body. It is a healthy food.
[0006] 請求項 2の本発明は、リンゴ酸、 L—パリン、 L—ロイシン、 L—イソロイシン、フィコシァニ ン、フィチン酸、 L一システィン、 L一メチォニン、エチレンジァミン、 EDTA、 ひ—リポ酸 、フラボノイド化合物、酒石酸、グノレコン酸、アルギン酸の内、少なくとも一種類以上 力 成る添加キレート剤が添加され、前記添加キレート剤は固体状又は流体状に形 成され、前記添加キレート剤が人体又は動物の体内に摂取されることにより、前記人 体又は動物の体内の有害重金属又は有害ミネラルを封鎖して前記有害重金属のキ レート化合物又は前記有害ミネラルのキレート化合物が形成され、前記有害重金属 又は前記有害ミネラルが前記人体又は動物の体内から***される請求項 1記載の健 康食品である。 [0006] The invention of claim 2 provides malic acid, L-parin, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cystine, L-methionine, ethylenediamine, EDTA, polylipoic acid, and flavonoids. At least one of a compound, tartaric acid, gnoreconic acid, and alginic acid is added, and the added chelating agent is formed into a solid or fluid, and the added chelating agent is added to the human or animal body. When ingested, the harmful heavy metal or harmful mineral in the human or animal body is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or the harmful mineral becomes 2. The healthy body according to claim 1, which is excreted from the human body or animal body. Kang food.
[0007] 請求項 3の本発明は、前記必須キレート剤又はキレート剤誘導材料物質、及び前記 添加キレート剤力 0. 001— 35. 0重量%である請求項 2記載の健康食品である。  [0007] The present invention according to claim 3 is the health food according to claim 2, wherein the essential chelating agent or the chelating agent-derived material, and the added chelating agent power is 0.001 to 35.0% by weight.
[0008] 請求項 4の本発明は、ビタミン、糖質のいずれか一種以上が添加される請求項 1又は [0008] In the present invention of claim 4, claim 1 or at least one of vitamins and carbohydrates is added.
2記載の健康食品である。  It is a health food according to 2.
[0009] 請求項 5の本発明は、前記ビタミンは、ビタミン Bl、ビタミン B2、ビタミン B6、ビタミン[0009] The present invention according to claim 5, wherein the vitamin is vitamin B1, vitamin B2, vitamin B6, vitamin
B12、葉酸のいずれか一種類以上より成り、前記糖質は、ダルコサミンである請求項B12, comprising at least one kind of folic acid, wherein the saccharide is dalcosamine.
4記載の健康食品である。 It is a health food described in 4.
[0010] 請求項 6の本発明は、ノ二が添加される請求項 1又は 2記載の健康食品である。 [0010] The sixth aspect of the present invention is the health food according to the first or second aspect, wherein Noji is added.
[0011] 請求項 7の本発明は、パウダー、顆粒、錠剤、又はペーストに形成され、或いは、前 記パウダー、前記顆粒がカプセルに収容される請求項 1又は 2記載の健康食品であ る。 [0011] The present invention according to claim 7 is the health food according to claim 1 or 2, which is formed into a powder, a granule, a tablet, or a paste, or the powder or the granule is contained in a capsule.
[0012] 請求項 8の本発明は、呈味剤として、果汁エキスであるボンタンエキス、ライチェキス 、リンゴ果汁、オレンジ果汁、ゆずエキス、ピーチフレーバー、ウメフレーバー、甘味 剤であるアセスルファム K、エリスリトーノレ、オリゴ糖類、マンノース、キシリトーノレ、異 性化糖類、茶成分である緑茶、ウーロン茶、バナバ茶、杜仲茶、鉄観音茶、ノ、トムギ 茶、アマチヤヅル茶、マコモ茶、昆布茶、及び、ヨーグルトフレーバー、ビタミン Cのレヽ ずれか一種類以上が添加される請求項 1又は 2記載の健康食品である。  [0012] The present invention according to claim 8 is characterized in that as a flavoring agent, a fruit juice extract, bontan extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, a sweetener, acesulfame K, erythritol, oligo Saccharides, mannose, xylitole, catabolized saccharides, tea components such as green tea, oolong tea, banaba tea, Tochu tea, Tei Kannon tea, noto, tom tea, amatiyaru tea, makomo tea, kelp tea, and yogurt flavor, vitamin C 3. The health food according to claim 1, wherein at least one kind of the food is added.
[0013] 請求項 9の本発明は、前記有害重金属は Cd、 Hg、 Pb、 Crのいずれか一種類以上 力 成り、前記有害ミネラルは Al、 Be、 Asのいずれか一種類以上から成る請求項 1 又は 2記載の健康食品である。  [0013] In the present invention according to claim 9, the harmful heavy metal is composed of at least one of Cd, Hg, Pb, and Cr, and the harmful mineral is composed of at least one of Al, Be, and As. It is a health food described in 1 or 2.
発明の効果  The invention's effect
[0014] 請求項 1の本発明によれば、必須キレート剤又はキレート剤誘導材料物質は、メチ ルスルフォニルメタン、クェン酸、 L—シスチン力 成り、必須キレート剤又はキレート 剤誘導材料物質は固体状又は流体状に形成され、必須キレート剤又はキレート剤誘 導材料物質が人体又は動物の体内に摂取されることにより、人体又は動物の体内の 有害重金属又は有害ミネラルを封鎖して有害重金属のキレートイヒ合物又は有害ミネ ラルのキレート化合物が形成され、有害重金属又は有害ミネラルが人体又は動物の 体内から***される。 According to the first aspect of the present invention, the essential chelating agent or the chelating agent-derived material is methylsulfonylmethane, citrate, L-cystine, and the essential chelating agent or the chelating agent-derived material is solid. Or, when the essential chelating agent or chelating agent-inducing substance is ingested into the human or animal body by being formed in a fluid form, it blocks harmful heavy metals or harmful minerals in the human or animal body to chelate harmful heavy metals. Substances or toxic minerals are formed, and harmful heavy metals or harmful minerals Excreted from the body.
このため、人体又は動物の体内に蓄積された有害重金属又は有害ミネラルの*** が促される。又、食品や食品添加物を含む食事等により、知らず知らずに人体又は 動物の体内に蓄積、沈着されて、様々な健康障害、疾病、例えば、癌、骨の異常、脳 障害、神経麻痺、アレルギー、腎臓障害、肝臓障害、内分泌/生殖異常、高血圧を誘 発する危険性の減少に大きく寄与することが期待される。さらに上記疾病、障害の改 善、治癒にも大いに寄与することができる。  Therefore, excretion of harmful heavy metals or harmful minerals accumulated in the human or animal body is promoted. In addition, foods and foods containing food additives accumulate and deposit in the human or animal body without your knowledge, and cause various health disorders and diseases such as cancer, bone abnormalities, brain disorders, nervous palsy, and allergies. , Kidney and liver disorders, endocrine / reproductive disorders, and reduced risk of inducing hypertension. Furthermore, it can greatly contribute to the improvement and cure of the above diseases and disorders.
[0015] 請求項 2の本発明によれば、リンゴ酸、 L一パリン、 L—ロイシン、 L一イソロイシン、フィコ シァニン、フィチン酸、 L一システィン、 L一メチォニン、エチレンジァミン、 EDTA、 ひ— リポ酸、フラボノイド化合物、酒石酸、ダルコン酸、アルギン酸の内、少なくとも一種類 以上から成る添加キレート剤が添加され、添加キレート剤は固体状又は流体状に形 成され、添加キレート剤が人体又は動物の体内に摂取されることにより、人体又は動 物の体内の有害重金属又は有害ミネラルを封鎖して有害重金属のキレートイヒ合物又 は有害ミネラルのキレート化合物が形成され、有害重金属又は有害ミネラルが人体 又は動物の体内から***される。 [0015] According to the present invention of claim 2, malic acid, L-parin, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cystine, L-methionine, ethylenediamine, EDTA, polylipoic acid , A chelating agent comprising at least one of flavonoid compounds, tartaric acid, dalconic acid, and alginic acid is added, and the added chelating agent is formed in a solid or fluid state. When ingested, harmful heavy metals or harmful minerals in the human body or animal body are blocked to form toxic heavy metal chelating compounds or toxic mineral chelate compounds, and the harmful heavy metals or harmful minerals are removed from the human or animal body. Excreted from
このため、人体又は動物の体内に蓄積された有害ミネラルの種類、人体又は動物の 体内の蓄積態様を勘案して、添加キレート剤の種類を選択、調整すること力 Sできる。  Therefore, it is possible to select and adjust the type of the added chelating agent in consideration of the type of harmful minerals accumulated in the human or animal body and the manner of accumulation in the human or animal body.
[0016] 請求項 3の本発明によれば、必須キレート剤又はキレート剤誘導材料物質、及び添 加キレート剤が、 0. 001— 35. 0重量0 /0である。 [0016] According to the present invention of claim 3, essential chelating agent or chelating agent derived materials materials, and added pressure chelating agent, 0.5 001 35. 0 weight 0/0.
このため、人体又は動物の体内に蓄積された有害ミネラルの種類、人体又は動物の 体内の蓄積態様を勘案して、必須キレート剤又はキレート剤誘導材料物質、及び添 加キレート剤の配合割合を選択、調整することができる。  Therefore, taking into account the type of harmful minerals accumulated in the human or animal body and the manner of accumulation in the human or animal body, the mixing ratio of the essential chelating agent or chelating agent-derived material and the added chelating agent is selected. , Can be adjusted.
[0017] 請求項 4の本発明によれば、健康食品は、ビタミン、糖質のいずれか一種以上が添 加される。 According to the present invention of claim 4, the health food is added with at least one of vitamins and carbohydrates.
このため、血管細胞が補強され、動脈硬化の予防に有用となる。  For this reason, vascular cells are reinforced, which is useful for preventing arteriosclerosis.
[0018] 請求項 5の本発明によれば、ビタミンは、ビタミン Bl、ビタミン B2、ビタミン B6、ビタミ ン B12、葉酸のいずれか一種類以上より成り、糖質は、ダルコサミンである。 According to the fifth aspect of the present invention, the vitamin comprises at least one of vitamin B1, vitamin B2, vitamin B6, vitamin B12, and folic acid, and the carbohydrate is dalcosamine.
このため、血管細胞が補強され、動脈硬化の予防に有用となる。 [0019] 請求項 6の本発明によれば、健康食品は、ノ二が添加される。 For this reason, vascular cells are reinforced, which is useful for preventing arteriosclerosis. [0019] According to the sixth aspect of the present invention, health food is added with Noji.
このため、血管の拡張作用がはかられる。  For this reason, a dilation effect of the blood vessel is achieved.
[0020] 請求項 7の本発明によれば、健康食品は、固体状であるパウダー、顆粒、錠剤に形 成され、或いは、パウダー、顆粒がカプセルに収容される。又、流体状であるペースト に形成される。 [0020] According to the present invention of claim 7, the health food is formed into solid powders, granules, or tablets, or the powders and granules are contained in a capsule. It is also formed into a paste that is in fluid form.
このため、健康食品は、投与の方法に適合した様々の形態に形成され、投与、摂取 が容易となる。  For this reason, health foods are formed into various forms suitable for the method of administration, making administration and ingestion easy.
[0021] 請求項 8の本発明によれば、呈味剤として、果汁エキスであるボンタンエキス、ライチ エキス、リンゴ果汁、オレンジ果汁、ゆずエキス、ピーチフレーバー、ウメフレーバー、 甘味剤であるアセスルファム K、エリスリトール、オリゴ糖類、マンノース、キシリトーノレ 、異性化糖類、茶成分である緑茶、ウーロン茶、バナバ茶、杜仲茶、鉄観音茶、ハト ムギ茶、アマチヤヅル茶、マコモ茶、昆布茶、及び、ヨーグルトフレーバー、ビタミン C のレ、ずれか一種類以上が添加される。  [0021] According to the present invention of claim 8, as a flavoring agent, a botan extract, a lychee extract, an apple juice, an orange juice, a yuzu extract, a peach flavor, a plum flavor, a sweetness agent, acesulfame K as a sweetener, Erythritol, oligosaccharides, mannose, xylitole, isomerized saccharides, green tea, oolong tea, banaba tea, junchu tea, iron guanyin tea, pigeon tea, amachiazul tea, makomo tea, kelp tea, yogurt flavor, vitamins One or more types of C are added.
有害重金属又は有害ミネラルの***目的のみでは、呈味剤をカ卩えない組成も本発 明の範囲である。***効果の有効性のためには中長期間の投与が好ましいので呈 味性が重要となる。呈味性の改善のために呈味剤が添加される。  A composition that does not remove the flavoring agent only for the purpose of excluding harmful heavy metals or harmful minerals is within the scope of the present invention. Taste is important because administration over a medium to long term is preferable for the effectiveness of the excretion effect. A flavoring agent is added to improve the taste.
このため、呈味剤の種類、添加量に応じた種々の呈味性を有し、呈味性が改善され 、中長期間の投与に供しやすい健康食品となる。  For this reason, the health food has various tastes according to the type and the amount of the flavoring agent added, the taste is improved, and the health food is easy to be used for medium- to long-term administration.
[0022] 請求項 9の本発明によれば、有害重金属は Cd、 Hg、 Pb、 Crのいずれか一種類以上 力 成り、有害ミネラルは Al、 Be、 Asのいずれか一種類以上から成る。 有害重金属 は、必須キレート剤又はキレート剤誘導材料物質、又は添加キレート剤により封鎖さ れ有害重金属のキレート化合物が形成され、又、有害ミネラルは必須キレート剤又は キレート剤誘導材料物質、又は添加キレート剤により封鎖され有害ミネラルのキレート 化合物が形成される。これにより、 Cd、 Hg、 Pb、 Crのいずれか一種類以上は、有害 重金属のキレート化合物として、又は Al、 Be、 Asのいずれか一種類以上は、有害ミ ネラルのキレートイ匕合物として夫々人体又は動物の体内力、ら***される。 According to the ninth aspect of the present invention, the harmful heavy metal is at least one of Cd, Hg, Pb, and Cr, and the harmful mineral is at least one of Al, Be, and As. Hazardous heavy metals are blocked by an essential chelating agent or chelating agent-derived material or an added chelating agent to form a toxic heavy metal chelating compound, and harmful minerals are an essential chelating agent or a chelating agent-derived material, or an added chelating agent. To form a toxic mineral chelate compound. As a result, one or more of Cd, Hg, Pb, and Cr are used as chelating compounds of harmful heavy metals, and one or more of Al, Be, and As are used as chelating compounds of harmful minerals. Or it is excreted in the body of the animal.
このため、人体又は動物の体内に蓄積された有害重金属又は有害ミネラルの*** が促される。又、食品や食品添加物を含む食事等により、知らず知らずに人体又は 動物の体内に蓄積、沈着されて、様々な健康障害、疾病、例えば、癌、骨の異常、脳 障害、神経麻痺、アレルギー、腎臓障害、肝臓障害、内分泌/生殖異常、高血圧を誘 発する危険性の減少に大きく寄与することが期待される。さらに上記疾病、障害の改 善、治癒にも大いに寄与することができる。 Therefore, excretion of harmful heavy metals or harmful minerals accumulated in the human or animal body is promoted. In addition, due to foods and foods containing food additives, etc. Danger of accumulating and depositing in the animal's body, causing various health disorders and diseases, such as cancer, bone abnormalities, brain disorders, nervous palsy, allergies, kidney disorders, liver disorders, endocrine / reproductive disorders, and high blood pressure Is expected to greatly contribute to the reduction of Furthermore, it can greatly contribute to the improvement and cure of the above diseases and disorders.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
以下、本発明を、その実施の形態に基づいて説明する。 Hereinafter, the present invention will be described based on the embodiments.
先ず、有害金属、及びミネラルの総***量の検査方法について説明する。 First, a method for examining the total excretion of harmful metals and minerals will be described.
(1)被験者対象: 成人男子 9名 (年齢 32— 67才)  (1) Subjects: 9 adult males (age 32-67)
(2)尿採取方法  (2) Urine collection method
初めに被験者に本発明の健康食品の摂取前日早朝尿を洗浄ポリコップに採取して もらい総***量を計り(夜間尿も含む)部分尿を PFA (フッ素樹脂加工)容器に保存 する、次に摂取当日は朝、夕と本発明の健康食品を摂取方法に沿って摂取してもら レ、、翌日早朝に前日尿と同じように採取し総***量を計り(夜間尿も含む)部分尿を P FA (フッ素樹脂加工)容器に保存する。 First, a subject collects urine in the morning in the morning before the ingestion of the health food of the present invention in a cleaning plastic cup, measures the total excretion (including nocturnal urine), stores the partial urine in a PFA (fluororesin processed) container, and then ingests In the morning, in the morning and evening, the health food of the present invention was ingested according to the method of ingestion, and in the early morning of the next day, the same amount as the previous day's urine was collected and the total excreted amount was measured (including nocturnal urine). Store in FA (fluororesin processing) container.
(3)検査方法  (3) Inspection method
[ELAN DRCII (パーキンエルマ一社の ICP—MS:誘導結合プラズマ質量分析計) による尿分析〕  [Urine analysis by ELAN DRCII (PerkinElmer ICP-MS: Inductively coupled plasma mass spectrometer)]
「前処理」  "Preprocessing"
1.検体が凍っている場合は解凍し、よく振る。  1. If the sample is frozen, thaw and shake well.
2. 50mlのファルコンチューブに 35ml程度採取し、蓋をして遠心分離機にかける。 2 800rcp lOmin  2. Collect about 35 ml into a 50 ml Falcon tube, cover and centrifuge. 2 800rcp lOmin
3.検体の沈殿物を吸わないように、上澄みを 4mlピペットにて採取し、別の 50mlの ファルコンチューブに入れる。  3. Collect the supernatant with a 4 ml pipette so as not to absorb the precipitate of the sample, and transfer it to another 50 ml Falcon tube.
4. AulOppm標準液 20 μ 1および、高純度硝酸 600 μ 1添加し、超純水にて 20gにメ スアップする。  4. Add 20 μl of AulOppm standard solution and 600 μl of high-purity nitric acid, and make up to 20 g with ultrapure water.
ブランクは生体試料を入れなレ、もののみとする。  Blanks should not contain biological samples.
「分析」 "Analysis"
1.ブランク繰り返し 20回測定の安定性評価 2.検量線測定による、直線性、強度、測定限界値確認 1. Stability evaluation of blank measurement 20 times 2.Confirmation of linearity, strength and measurement limit value by calibration curve measurement
3.試料繰り返し測定  3.Repeated sample measurement
4.試料 5mlを前処理したものに、全測定元素の 2点測定による回収率評価  4.Evaluation of recovery rate by 2-point measurement of all measured elements on pre-treated 5 ml sample
5.試料量を 2.5ml, 5mlと希釈倍率を変えたときの同一確認  5. The same confirmation when the sample volume is changed to 2.5ml, 5ml and dilution ratio
次に、実施例 1一 11の成分、その検查結果、及び結果のまとめについて説明する。 本発明における実施例 1一 11において、健康食品摂取前後の就寝中、尿中有害ミ ネラル、ならびに尿中ミネラル***量について以下にまとめる。なお、各データにお いて正規性の検定を行ない、正規分布に従うときは、対応のある t検定を行なった。 各データが正規分布に従わないときは、ウィルコクソン符号付順位和検定を行なった Next, the components of Example 11-11, the detection results thereof, and a summary of the results will be described. In Examples 11 to 11 of the present invention, harmful minerals in urine and excretion of minerals in urine before and after ingestion of health foods are summarized below. A normality test was performed for each data, and when the data followed a normal distribution, a paired t-test was performed. When each data did not follow the normal distribution, a Wilcoxon signed rank sum test was performed.
。それぞれは、危険率 5%で検定した。 . Each was tested at a 5% risk factor.
(注記)以下の各検査結果表において、最下行欄 (Av)は、被験者 9人の各列データ の単純平均値を示す。  (Note) In each of the following test result tables, the bottom row (Av) shows the simple average of the data of each column of 9 subjects.
実施例 1  Example 1
[0024] 実施例 1における健康食品の成分は、  [0024] The components of the health food in Example 1 are as follows:
メチルスルフォニルメタン(42· 5)mg、クェン酸(50)mg、 L一シスチン(2· 5)mgに、 リンゴ酸(50)mg、 L一パリン(125)mg、 L一口イシン(125)mg、 L一イソロイシン(125 )mg、フィコシァニン(25) mg、フィチン酸(0)mg、 L一システィン(0)mg、 L一メチォ ニン(0)mg、エチレンジァミン(0)mg、 EDTA(0)mg、ひ—リポ酸(0)mg、フラボノィ ド化合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ 、さらに、ビタミン Bl(0)mg、ビタミン B2(0)mg、ビタミン B6(0)mg、ビタミン B12(0 ) zg、葉酸(0) zg、グノレコサミンが(0)mg、ノ二が(0)mg及び、呈味剤は、グレープ フルーツ果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。  Methylsulfonylmethane (42.5 mg), citric acid (50 mg), L-cystine (2.5 mg), malic acid (50) mg, L-parin (125) mg, L-mouth isine (125) mg , L-isoleucine (125) mg, phycocyanin (25) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (0) mg, ethylenediamine (0) mg, EDTA (0) mg , Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg, and vitamin Bl (0) mg, vitamin B2 (0) mg, Vitamin B6 (0) mg, Vitamin B12 (0) zg, folic acid (0) zg, (0) mg gnorecosamine, (0) mg noni, and the flavoring agent is grapefruit juice (50) mg, and oligosaccharide (1500) mg.
検査結果;  Inspection results;
[0025] [表 1] 就寝中、 時間当たりの尿中有害ミネラル***量 gZhr.)
Figure imgf000009_0001
[Table 1] Urinary toxic mineral excretion per hour during bedtime gZhr.)
Figure imgf000009_0001
[表 2] [Table 2]
表 2 就寝中、 時間当たりの尿中ミネラル***量 gZhr.)
Figure imgf000009_0002
(Table 2 Urinary mineral excretion per hour during bedtime gZhr.)
Figure imgf000009_0002
実施例 1では表 1に示されるように、ヒ素 (As)では、図 2に示されるように、平均値に おいて 10. 22( zg/hr)力ら 21.46 ( μ g/hr)と約 2. 1倍の***量の増加が認めら れた。また、この結果を有意差検定すると t検定において p値 0.016 (pく 0.05)と有 意な差をもって摂取後にヒ素***量の増加があることが証明された。同様に各有害ミ ネラルについても検討すると、表 1に示されるように、水銀 (Hg)では、図 3に示される ように、平均値では 0· 106( §/1^)カら0. 160( §/1^)と約1. 5倍の***量の 増加が認められた。 In Example 1, as shown in Table 1, the average value of arsenic (As) was 10.22 (zg / hr) and 21.46 (μg / hr), as shown in Figure 2. 2. One-time increase in excretion was observed. In addition, a significant difference test of these results demonstrated that there was a significant difference in p-value of 0.016 (p-0.05) in the t-test and an increase in arsenic excretion after ingestion. Similarly, when examining each harmful mineral, as shown in Table 1, the average value of mercury (Hg) was 0.106 (§ / 1 ^) and 0.160, as shown in Fig. 3. (§ / 1 ^) and about 1.5 times the amount of excretion An increase was observed.
表 1に示されるように、カドミウム(Cd)においては、図 4に示されるように、平均値で は 0· 047( §/1^)カら0.070( /1 §/ )と水銀0¾)同様に約1.5倍の***量の 増加が認められた。 As shown in Table 1, in the cadmium (Cd), as shown in FIG. 4, 0 - 047 in average (§ / 1 ^) shell 0.070 (/ 1 § /) mercury 0¾) Similarly An increase in excretion of about 1.5 times was observed in all animals.
表 1に示されるように、鉛(Pb)においては、図 1に示されるように、平均値では 0.0 62( §/111 カ、ら0.083( §/}^)と約1.3倍の***量の増加が認められた。 アルミニウム(A1)においては、表 1に示されるように、平均値では 0.364( xg/hr) 力、ら 0.374 ( μ g/hr)とわずかに***量の増加が認められた。 As shown in Table 1, in the lead (Pb), as shown in FIG. 1, the average value 0.0 62 / 111 mosquitoes, La 0.083 /} ^) and about 1.3 times the excretion As shown in Table 1, the excretion of aluminum (A1) was slightly increased to 0.364 (xg / hr) and 0.374 (μg / hr) on average, as shown in Table 1. Was.
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛 (Pb)、においては有意差 (pく 0.05)をもって、本発明の健康食品摂取前 より摂取後の尿中有害ミネラル***量の増加が認められた。  When these harmful mineral excretions are tested in the same manner as arsenic, mercury (Hg), cadmium (Cd), and lead (Pb) have a significant difference (p <0.05). Increased the excretion of harmful minerals in urine.
[0028] 一方、尿中ミネラル***量では、表 2に示されるように、カルシウム(Ca)において、 平均値では 7.298 (μ g/hr)力ら 12.241 (/i g/hr)と増カロして約 1.6倍の変ィ匕カ S あったものの、この結果にヒ素同様の検定を行うと、有意差は得られない結果となつ た。 (t検定、 pく 0.05で 0.111) [0028] On the other hand, as shown in Table 2, in urinary mineral excretion, the average value of calcium (Ca) increased from 7.298 (μg / hr) to 12.241 (/ ig / hr). Although the result was about 1.6 times as large as that of S, the same test as arsenic showed no significant difference. (T-test, p-0.05 at 0.111)
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p<0.05)は得られなかつ た。  Similarly, as a result of performing a test for changes in urine mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained.
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 2  Example 2
[0029] 実施例 2における健康食品の成分は、  [0029] The components of the health food in Example 2 are as follows:
メチルスルフォニルメタン(50) mg、クェン酸(50)mg、 L一シスチン(2.5)mgに、リン ゴ酸(50)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50)mg、フ ィコシァニン(25)mg、フィチン酸(0)mg、 L一システィン(0)mg、 L一メチォニン(5) m g、エチレンジァミン(0)mg、 EDTA(0)mg、 α_リポ酸(0)mg、フラボノイド化合物( 0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さらに、 ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン Bl 2 (3) /i g、葉 酸(20) /ig、ダルコサミンが(10) mg、ノニカ S(0)mg及び、呈味剤は、オレンジ果汁 が(50) mg、オリゴ糖が(1500) mg添加されて成る。 Methylsulfonylmethane (50) mg, citric acid (50) mg, L-cystine (2.5) mg, malic acid (50) mg, L-parin (50) mg, L-bite isine (50) mg, L-cystine Isoleucine (50) mg, phycocyanin (25) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, α_ Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added. Vitamin Bl (3) mg, Vitamin B2 (3) mg, Vitamin B6 (3) mg, Vitamin Bl 2 (3) / ig, folic acid (20) / ig, darcosamine (10) mg, Nonika S (0) The mg and flavoring agents consist of (50) mg of orange juice and (1500) mg of oligosaccharides.
検査結果; Inspection results;
[表 3] 就寝中、 時間当たりの尿中有害ミネラル***量 ( g/hr.)
Figure imgf000011_0001
[Table 3] Urinary toxic mineral excretion per hour during bedtime (g / hr.)
Figure imgf000011_0001
実施例 2について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 3に示されるように、ヒ素(As)では、平均値においても 8· 66(/ig/hr)から 18.57 ( / g/hr)と約 2. 1倍の***量の増加が認められた。また、この結果を有意差検定す ると t検定において p値 0. 0096 (p< 0. 05)で有意な差をもって摂取後にヒ素*** 量の増加があることが証明された。同様に各有害ミネラルについても検討すると、表 3 に示されるように、水銀 (Hg)では、平均値では 0. 083 ( §71 1 カ、ら0. 152 ( z g/ hr)と約 1. 83倍の***量の増加が認められた。 For Example 2, the harmful mineral excretions at bedtime before and after ingestion of health foods are summarized.As shown in Table 3, the average value of arsenic (As) was 8.6 (/ ig / hr) to 18.57 ( / g / hr) and about a 2.1-fold increase in excretion. In addition, a significant difference test of the results showed that there was an increase in arsenic excretion after ingestion with a significant difference in p value of 0.0096 (p <0.05) in the t test. Similarly, when considering also the harmful minerals, as shown in Table 3, the mercury (Hg), Mean value 0. 083 71 1 month at about a et 0. 152 (zg / hr) 1. 83 A two-fold increase in excretion was observed.
表 3に示されるように、カドミウム(Cd)においては、平均値では 0. 039 ( z g/hr)力、 ら 0. 075 ( §71 1 と水銀(1¾)同様に約1. 92倍の***量の増加が認められた。 表 3に示されるように、鉛(Pb)においては、
Figure imgf000012_0001
As shown in Table 3, in the cadmium (Cd), the average value is 0. 039 (zg / hr) force, et 0. 075 71 1 mercury (1¾) Similarly to about 1.92 times the excretion As shown in Table 3, for lead (Pb),
Figure imgf000012_0001
00 ( μ g/hr)と約 1. 42倍の***量の増加が認められた。  The excretion was increased by about 1.42 times to 00 (μg / hr).
アルミニウム(A1)においては、表 3に示されるように、平均値では 0. 348 ( μ g/hr) 力、ら 0. 576 ( μ g/hr)と***量の増加が認められた。  In aluminum (A1), as shown in Table 3, the average value was 0.348 (μg / hr), and the increase in excretion was 0.576 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)におレ、て有意差 (pく 0· 05)をもって、本発明の健 康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is examined in the same manner as arsenic, mercury (Hg), cadmium (Cd), lead (Pb), and aluminum (A1) have significant differences (p Increased excretion of harmful minerals in urine after ingestion of the healthy food of the invention was observed before ingestion.
[0033] 一方、尿中ミネラル***量では、表 4に示されるように、カルシウム(Ca)において、 平均値では 9· 195 ( μ g/hr)力ら 10. 342 ( /i g/hr)と増カロして約 1. 1倍の変化で あり、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得られない結果 となった。 (t検定、 pく 0. 05で 0. 345) On the other hand, as shown in Table 4, the urinary mineral excretion of calcium (Ca) was 9.195 (μg / hr) and 10.342 (/ ig / hr) in average. The increase in calorie was about a 1.1-fold change. When a test similar to arsenic was performed on this result, no significant difference was obtained in the t test. (T-test, p-0.05 at 0.05 and 0.345)
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p< 0. 05)は得られなかつ た。  Similarly, a test was conducted for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo) for changes in urinary mineral excretion, and no significant difference (p <0.05) was obtained. .
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって、摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  There is a statistically significant difference between the intake and non-ingestion of the health food of the present invention in daily life, and the ingestion of harmful minerals in urine increases with a statistically significant difference. It is considered a food that helps maintain and improve health.
実施例 3  Example 3
[0034] 実施例 3における健康食品の成分は、  [0034] The components of the health food in Example 3 are as follows:
メチルスルフォニルメタン(50) mg、クェン酸(50) mg、 L一シスチン(2· 5) mgに、リン ゴ酸(50) mg、 L一パリン(50) mg、 L一口イシン(50) mg、 L一イソロイシン(50) mg、フ ィコシァニン(2· 5)mg、フィチン酸(5)mg、 L システィン(0)mg、 L メチォニン(5) mg、エチレンジァミン(0)mg、 EDTA(5)mg、 α リポ酸(0)mg、フラボノイド化合 物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さら に、ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン B12(3) g 、葉酸(20) zg、ダルコサミンが(10) mg、ノ二が(0)mg及び、呈味剤は、オレンジ果 汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 To methylsulfonylmethane (50) mg, citric acid (50) mg, L-cystine (2.5) mg, malic acid (50) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg, Icosyanin (2.5 mg), phytic acid (5) mg, L cysteine (0) mg, L methionine (5) mg, ethylenediamine (0) mg, EDTA (5) mg, α-lipoic acid (0) mg, flavonoids Compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added, and vitamin Bl (3) mg, vitamin B2 (3) mg, and vitamin B6 (3) ) mg, vitamin B12 (3) g, folic acid (20) zg, darcosamine (10) mg, noni (0) mg, and flavoring agents: orange juice (50) mg, oligosaccharide ( 1500) mg.
検査結果; Inspection results;
[表 5] 就寝中、 時間当たりの尿中有害ミネラル***量 ( ig/hr.) [Table 5] Urinary toxic mineral excretion per hour during bedtime (ig / hr.)
Figure imgf000013_0001
Figure imgf000013_0001
[表 6] [Table 6]
就寝中、 時間当たりの尿中ミネラル***量 ( ig/hr.) Urinary mineral excretion per hour during bedtime (ig / hr.)
Figure imgf000014_0001
Figure imgf000014_0001
[0037] 実施例 3について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 5に示されるように、ヒ素(As)では、平均値においても 10· 09(/ig/hr)力ら 19· 60 (/ig/hr)と約 2.1倍の***量の増加が認められた。また、ウィルコックソン検定では 有意な差をもって摂取後にヒ素***量の増加があることが証明された。同様に各有 害ミネラルについても検討すると、表 5に示されるように、水銀 (Hg)では、平均値で は 0.093( §711 カ、ら0.164( §711 と約1.7倍の***量の増加が認められた 表 5に示されるように、カドミウム(Cd)においては、平均値では 0.040( zg/hr)力、 ら 0.070( §/111 と水銀(1¾)同様に約1.8倍の***量の増加が認められた。 表 5に示されるように、鉛(Pb)においては、平均値では 0.054( zg/hr)から 0.0 86 ( μ g/hr)と約 1.6倍の***量の増加が認められた。 [0037] For Example 3, the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized. As shown in Table 5, the average value of arsenic (As) was 10 · 09 (/ ig / hr) as shown in Table 5. The excretion was increased by about 2.1 times to 19 · 60 (/ ig / hr). The Wilcoxon test also demonstrated a significant difference in arsenic excretion after ingestion. Similarly, if also consider the harmful minerals, as shown in Table 5, the mercury (Hg), 0.093 (§711 months in average, an increase in et 0.164 711 and about 1.7 times the excretion As shown in Table 5, the average value of cadmium (Cd) was 0.040 (zg / hr), and 0.070 ( § / 111 and mercury (1¾) increased about 1.8 times as much as that of mercury (1¾). As shown in Table 5, the average value of lead (Pb) increased from 0.054 (zg / hr) to 0.086 (μg / hr), a 1.6-fold increase. Was.
アルミニウム(A1)においては、平均値では 0.332 (μ g/hr)力、ら 0.477 (μ g/hr) とわずかに***量の増加が認められた。  For aluminum (A1), the excretion was slightly increased, with an average value of 0.332 (μg / hr) and 0.477 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム( Cd)、鉛 (Pb)、においては有意差 (pく 0.05)をもって、本発明の健康食品摂取前 より摂取後の尿中有害ミネラル***量の増加が認められた。  When these harmful mineral excretions are tested in the same manner as arsenic, mercury (Hg), cadmium (Cd), and lead (Pb) have significant differences (p <0.05), and before and after ingestion of the health food of the present invention. Increased the excretion of harmful minerals in urine.
[0038] 一方、尿中ミネラル総***量では、表 6に示されるように、カルシウム(Ca)において 、平均値では 6.381 (/ig/hr)力ら 6.768 ( /i g/hr)と増カロして約 1.06倍の変ィ匕 があった。この結果にヒ素同様の検定を行うと、 t検定において、有意差は得られない 結果となった。 On the other hand, as shown in Table 6, the total urinary mineral excretion increased by 6.381 (/ ig / hr) and 6.768 (/ ig / hr) on average in calcium (Ca). About 1.06 times was there. When a test similar to arsenic was performed on these results, no significant difference was obtained in the t-test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p<0.05)は得られなかつ た。  Similarly, as a result of performing a test for changes in urine mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained.
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 4  Example 4
[0039] 実施例 4における健康食品の成分は、  [0039] The components of the health food in Example 4 were as follows:
メチルスルフォニルメタン(50) mg、クェン酸(100)mg、 L一シスチン(2· 5)mgに、リ ンゴ酸(50)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50)mg、 フィコシァニン(2· 5)mg、フィチン酸(5)mg、 L—システィン(0)mg、 L一メチォニン( 5)mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α_リポ酸(0)mg、フラボノイド化 合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さ らに、ヒ、、タミン Bl(3)mg、ヒ、、タミン B2(3)mg、ヒ、、タミン B6 (3)mg、ヒ、、タミン B12 (3) μ g、葉酸(20) zg、ダルコサミンが(10) mg、ノ二が(0)mg及び、呈味剤は、オレンジ 果汁が 50mg、オリゴ糖が(1500) mg添加されて成る。  To methylsulfonylmethane (50) mg, citric acid (100) mg, L-cystine (2.5) mg, linoleic acid (50) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg, phycocyanin (2.5) mg, phytic acid (5) mg, L-cystine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg , Α_ lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg. (3) mg, argentine, tamamine B2 (3) mg, argentine, tamamine B6 (3) mg, argentine, talc B12 (3) μg, folic acid (20) zg, dalcosamine (10) mg, (2) (2) and the flavoring agent consist of 50 mg of orange juice and (1500) mg of oligosaccharide.
検査結果;  Inspection results;
[0040] [表 7] [Table 7]
表 7 就寝中、 時間当たりの尿中有害ミネラル***量 (/zg/hr.)Table 7 Urinary toxic mineral excretion per hour during bedtime (/ zg / hr.)
[0041][0041]
Figure imgf000016_0001
Figure imgf000016_0001
[0042] 実施例 4について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 7に示されるように、ヒ素(As)では、平均値においても 13· 76(/ig/hr)力ら 19· 34 ( zg/hr)と約 1.4倍の***量の増加が認められた。また、この結果を有意差検定 すると、ウィルコックソン検定では有意な差をもって摂取後にヒ素***量の増加がある こと力 S証明された。同様に各有害ミネラルについても検討すると、表 7に示されるよう に、水銀(Hg)では、平均値では 0. 099( §/111 カ、ら0. 135( §/111 と糸勺1. 36 倍の***量の増加が認められた。 表 7に示されるように、カドミウム(Cd)においては、平均値では 0· 047(/ig/hr)力 ら 0.070(Aig/hr)と水銀 (Hg)同様に約 1.5倍の***量の増加が認められた。 表 7に示されるように、鉛(Pb)においては、
Figure imgf000017_0001
[0042] For Example 4, the amount of harmful mineral excretion during bedtime before and after ingestion of the health food was summarized. As shown in Table 7, the average value of arsenic (As) was 13.76 (/ ig / hr). The excretion was increased by about 1.4-fold to 19 · 34 (zg / hr). In addition, a significant difference test of the results showed that the Wilcoxon test showed a significant difference in the increase in arsenic excretion after ingestion with a significant difference. Similarly, when each harmful mineral is examined, as shown in Table 7, the average value of mercury (Hg) is 0.099 ( § / 111 mosquitoes, etc., 0.135 ( § / 111 and 1.36%). A two-fold increase in excretion was observed. As shown in Table 7, the average value of cadmium (Cd) is 0.047 (/ ig / hr), 0.070 (Aig / hr), and the excretion is about 1.5 times as high as mercury (Hg). Was observed. As shown in Table 7, for lead (Pb),
Figure imgf000017_0001
79 ( μ g/hr)と約 1.6倍の***量の増加が認められた。  The excretion was increased by 79 (μg / hr), about 1.6 times.
アルミニウム(A1)においては、平均値では 0.318 (μ g/hr)力、ら 0.450 (μ g/hr) と***量の増加が認められた。  In aluminum (A1), the mean excretion was 0.318 (μg / hr), and the excretion was 0.450 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛 (Pb)、においては有意差をもって、本発明の健康食品摂取前より摂取後 の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is examined in the same way as arsenic, mercury (Hg), cadmium (Cd), and lead (Pb) have significant differences, and the urinary harmful minerals before and after ingesting the health food of the present invention. Increased excretion was observed.
[0043] 一方、尿中ミネラル***量では、表 8に示されるように、カルシウム(Ca)におレ、て、 平均値では 9.773( xgZhr)力、ら 10.811 ( μ g/hr)と増カロして約 1.1倍の変化が あったものの、この結果にヒ素同様の検定を行うと、 t検定において有意差は得られな い結果となった。 [0043] On the other hand, as shown in Table 8, urinary mineral excretion was increased to 9.773 (xgZhr) and 10.811 (μg / hr) as the average value for calcium (Ca). Although there was a change of about 1.1 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p<0.05)は得られなかつ た。  Similarly, as a result of performing a test for changes in urine mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained.
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urine excretion of harmful minerals increases when the health food of the present invention is taken and not taken in daily life when taken with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 5  Example 5
[0044] 実施例 5における健康食品の成分は、  [0044] The components of the health food in Example 5 are as follows:
メチルスルフォニルメタン(50) mg、クェン酸(50)mg、 L一シスチン(2.5)mgに、リン ゴ酸(100)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50)mg、 フィコシァニン(2.5)mg、フィチン酸(0)mg、 L—システィン(0)mg、 L_メチォニン( 5)mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α_リポ酸(0)mg、フラボノイド化 合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さ らに、ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン B12 (3) μ g、葉酸(20) /ig、ダルコサミンが(10) mg、ノ二が(10) mg及び、呈味剤は、グレー プ果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 To methylsulfonylmethane (50) mg, citric acid (50) mg, L-cystine (2.5) mg, malic acid (100) mg, L-parin (50) mg, L-bite isine (50) mg, L-cystine Isoleucine (50) mg, phycocyanin (2.5) mg, phytic acid (0) mg, L-cysteine (0) mg, L_methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, α_lipo Acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added, and vitamin Bl (3) mg, vitamin B2 (3) mg, vitamin B6 (3) mg, vitamin B12 (3) μg, folic acid (20) / ig, (10) mg for dalcosamine, (10) mg for noni, and the flavoring agent is gray (50) mg of fruit juice and (1500) mg of oligosaccharide are added.
検査結果;  Inspection results;
[0045] [表 9] [Table 9]
表 9 就寝中、 時間当たりの尿中有害ミネラル***量 g/hr. )  (Table 9 Urinary toxic mineral excretion per hour during bedtime g / hr.)
[0046] [0046]
Figure imgf000018_0001
Figure imgf000018_0001
実施例 5について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 9に示されるように、ヒ素(As)では、平均値においても 8. 20 ( z g/hr)から 17. 13 ( z g/hr)と約 2. 1倍の***量の増加が認められた。また、この結果を有意差検定す ると、ウィルコックソン検定では有意な差をもって摂取後にヒ素***量の増加があるこ とが証明された。同様に各有害ミネラルについても検討すると、表 9に示されるように 、水銀(Hg)では、平均値では 0. 107( §/1^)カら0. 169( §/1^)と約1. 5倍 の***量の増加が認められた。 For Example 5, the harmful mineral excretions at bedtime before and after ingesting the health food were summarized. As shown in Table 9, the average value of arsenic (As) was 8.20 (zg / hr) to 17.13 (zg / hr) and about a 2.1-fold increase in excretion. In addition, a significant difference test of this result shows that the Wilcoxon test showed a significant difference in arsenic excretion after ingestion. And it was proved. Similarly, when examining each harmful mineral, as shown in Table 9, the average value of mercury (Hg) was 0.107 (§ / 1 ^), 0.169 (§ / 1 ^) A five-fold increase in excretion was noted.
表 9に示されるように、カドミウム(Cd)においては、平均値では 0. 050( zg/hr)か ら 0. 078( §/111 と水銀(1¾)同様に約1. 5倍の***量の増加が認められた。 表 9に示されるように、鉛(Pb)においては、平均値では 0. 059( zg/hr)力 0. 0 82 ( μ g/hr)と約 1. 3倍の***量の増加が認められた。 As shown in Table 9, the excretion of cadmium (Cd) is about 1.5 times the average from 0.050 (zg / hr) to 0.078 ( § / 111 and mercury (1¾)). As shown in Table 9, the average value of lead (Pb) was 0.059 (zg / hr), 0.082 (μg / hr), and about 1.3 times higher. Increased excretion was observed.
アルミニウム(A1)においては、表 9に示されるように、平均値では 0. 415 (μ g/hr) 力、ら 0. 738 ( μ g/hr)と***量の増加が認められた。  In aluminum (A1), as shown in Table 9, the average value was 0.415 (μg / hr), and the average excretion was 0.738 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)におレ、ては有意差 (pく 0. 05)をもって、本発明の 健康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is tested in the same way as arsenic, mercury (Hg), cadmium (Cd), lead (Pb), and aluminum (A1) have significant differences (p <0.05). An increase in urinary harmful mineral excretion after ingestion of the health food of the present invention was observed before ingestion.
[0048] 一方、尿中ミネラル総***量では、表 10に示されるように、カルシウム(Ca)におい て、平均値では 6· 976 (/i g/hr)力ら 10. 462 ( /i g/hr)と増カロして約 1. 5倍の変 ィ匕があったものの、この結果にヒ素同様の検定を行うと、 t検定において有意差は得 られない結果となった。 [0048] On the other hand, as shown in Table 10, the total urinary mineral excretion was 10.462 (/ ig / hr) for calcium (Ca) at an average value of 6 · 976 (/ ig / hr). ) And increased by about 1.5 times, but when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差は得られなかった。  Similarly, no significant difference was obtained for the changes in urinary mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo).
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 6  Example 6
[0049] 実施例 6における健康食品の成分は、  [0049] The components of the health food in Example 6 were as follows:
メチルスルフォニルメタン(60) mg、クェン酸(50)mg、 L一シスチン(2. 5)mgに、リン ゴ酸(50)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50)mg、フ ィコシァニン(2· 5)mg、フィチン酸(0)mg、 L一システィン(0)mg、 L一メチォニン(5) mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α—リポ酸(0)mg、フラボノイド化合 物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さら に、ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン B12(3) /i g 、葉酸(20) /ig、ダルコサミンが(10) mg、ノ二が(10) mg及び、呈味剤は、グレープ 果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 To methylsulfonylmethane (60) mg, citric acid (50) mg, L-cystine (2.5) mg, malic acid (50) mg, L-parin (50) mg, L-mouth isine (50) mg, L one isoleucine (50) mg, off Ikoshianin (2 · 5) mg, phytic acid (0) mg, L one cysteine (0) mg, L one Mechionin (5) m g, Echirenjiamin (0) mg, EDTA (0 ) mg, α-lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg. In addition, vitamin Bl (3) mg, vitamin B2 (3) mg, vitamin B6 (3) mg, vitamin B12 (3) / ig, folic acid (20) / ig, darcosamine (10) mg, and noni (10 ) mg and flavoring agents consist of (50) mg of grape juice and (1500) mg of oligosaccharides.
検査結果; Inspection results;
[表 11] [Table 11]
表 1 1 就寝中、 時間当たりの尿中有害ミネラル***量 ( _tg/hr.)
Figure imgf000020_0001
Table 11 1 Urinary toxic mineral excretion per hour during bedtime (_tg / hr.)
Figure imgf000020_0001
実施例 6について、健康食品摂取前後の就寝中有害ミネラル総***量をまとめると、 表 11に示されるように、ヒ素(As)では、平均値においても 10· 27(/ig/hr)力ら 16 . 65 ( /1 §/1^)と約1. 6倍の***量の増加が認められた。また、この結果を有意差 検定すると、 t検定において p値 0. 032 (p< 0. 05)と有意な差をもって摂取後にヒ素 ***量の増加があることが証明された。同様に各有害ミネラルについても検討すると 、表 11に示されるように、水銀(Hg)では、平均ィ直では 0. 098 ( ^ §/^)カら0. 139 ( μ g/hr)と約 1. 4倍の***量の増加が認められた。 Table 6 summarizes the total excretion of harmful minerals during bedtime before and after ingesting health foods for Example 6, and as shown in Table 11, the average value of arsenic (As) was 10 · 27 (/ ig / hr). 16 The excretion was increased by about 1.6 times, 65 (/ 1 § / 1 ^). In addition, a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference from the p-value of 0.032 (p <0.05) in the t-test. Similarly, when examining each harmful mineral, as shown in Table 11, the average value of mercury (Hg) was 0.098 (^ § / ^) and 0.139 (μg / hr). 1. A four-fold increase in excretion was observed.
表 11に示されるように、カドミウム(Cd)においては、平均値では 0. 047 ( μ g/hr) 力、ら 0. 077 ( §71 1 と約1. 6倍の***量の増加が認められた。 As shown in Table 11, in the cadmium (Cd), 0. 047 (μ g / hr) force, is increased et 0. 077 71 1 to about 1. 6 times excretion observed in the mean value Was done.
表 11に示されるように、鉛(Pb)においては、平均値では 0. 072 ( μ g/hr)力 0. 093 ( μ g/hr)と約 1.3倍の***量の増加が認められた。  As shown in Table 11, the average excretion of lead (Pb) was 0.072 (μg / hr) and 0.093 (μg / hr). .
アルミニウム(A1)においては、表 11に示されるように、平均値では 0. 333 ( μ g/hr) 力、ら 0. 587 ( μ g/hr)と***量の増加が認められた。  For aluminum (A1), as shown in Table 11, the average value was 0.333 (μg / hr), and the average excretion was 0.587 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)においては有意差 (ρ< 0· 05)をもって、本発明の 健康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  Assays of these harmful mineral excretions in the same manner as arsenic showed that the mercury (Hg), cadmium (Cd), lead (Pb) and aluminum (A1) had a significant difference (ρ <0.05), An increase in urinary harmful mineral excretion after ingestion was observed before ingestion of food.
[0053] 一方、尿中ミネラル***量では、表 12に示されるように、カルシウム(Ca)において 、平均値では 8· 362 ( /i g/hr)力ら 10. 689 ( /i g/hr)と増カロして約 1. 3倍の変化 があったものの、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得ら れない結果となった。 On the other hand, as shown in Table 12, the urinary mineral excretion amount was 8.362 (/ ig / hr) and the average value was 10.689 (/ ig / hr) for calcium (Ca). Although the increase in calories resulted in a change of about 1.3 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p< 0. 05)は得られなかつ た。  Similarly, a test was conducted for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo) for changes in urinary mineral excretion, and no significant difference (p <0.05) was obtained. .
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 7  Example 7
[0054] 実施例 7における健康食品の成分は、  [0054] The components of the health food in Example 7 are as follows:
メチルスルフォニルメタン(50) mg、クェン酸(100) mg、 L一シスチン(2· 5) mgに、リ ンゴ酸(100) mg、 L一パリン(50) mg、 L一口イシン(50) mg、 L一イソロイシン(50) mg 、フィコシァニン(2.5)mg、フィチン酸(0)mg、 L システィン(0)mg、 L メチォニン (5)mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α_リポ酸(0)mg、フラボノイド化 合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さ らに、ヒ、、タミン Bl(3)mg、ヒ、、タミン B2(3)mg、ヒ、、タミン B6 (3)mg、ヒ、、タミン Bl 2 (3) μ g、葉酸(20)mg、グノレコサミンが(10) mg、ノ二が(10) mg及び、呈味剤は、ピーチ 果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 Methylsulfonylmethane (50) mg, citric acid (100) mg, L-cystine (2.5) mg, linoleic acid (100) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg Phycocyanin (2.5) mg, phytic acid (0) mg, L cysteine (0) mg, L methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, α_lipoic acid (0) mg, flavonoids Compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added, and arsenic, thiamine Bl (3) mg, arsenic, thamin B2 ( 3) mg, hi, tamine B6 (3) mg, hi ,, tamine Bl 2 (3) μg, folate (20) mg, gunorecosamine (10) mg, noni (10) mg and taste The preparation consists of (50) mg of peach juice and (1500) mg of oligosaccharides.
検査結果; Inspection results;
[表 13] [Table 13]
表 13 就寝中、 時間当たりの尿中有害ミネラル***量 g/hr.)  (Table 13 Urinary toxic mineral excretion per hour during bedtime g / hr.)
Figure imgf000022_0001
Figure imgf000022_0001
[表 14] [Table 14]
表 14 就寝中、 時間当たりの尿中ミネラル***量 (^g/hr.) Table 14 Urinary mineral excretion per hour during bedtime (^ g / hr.)
Figure imgf000023_0002
Figure imgf000023_0002
[0057] 実施例 7について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 13に示されるように、ヒ素(As)では、平均ィ直におレヽても 11.81(/ig/hr)力ら 19.5 2 §/^)と約1.7倍の***量の増加が認められた。また、この結果を有意差検定 すると t検定において p値 0.010 (pく 0.05)と有意な差をもって摂取後にヒ素*** 量の増加があることが証明された。同様に各有害ミネラルについても検討すると、表 1 3に示されるように、水銀 (Hg)では、
Figure imgf000023_0001
193( zg /hr)と約 1.7倍の***量の増加が認められた。
For Example 7, the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized. As shown in Table 13, the arsenic (As) was 11.81 (/ ig / hr) was 19.5 2 § / ^), an increase of about 1.7 times in excretion. In addition, a significant difference test of the results proved that there was an increase in arsenic excretion after ingestion with a significant difference of p-value of 0.010 (p-0.05) in the t-test. Similarly, considering each harmful mineral, as shown in Table 13, mercury (Hg)
Figure imgf000023_0001
The excretion was increased by about 193 (zg / hr), about 1.7 times.
表 13に示されるように、カドミウム(Cd)においては、平均値では 0.04( zg/hr)力、 ら 0.067( §711 と水銀(1¾)同様に約1.5倍の***量の増加が認められた。 表 13に示されるように、鉛(Pb)においては、平均値では 0.063( zg/hr)力 0. 092 ( μ g/hr)と約 1.5倍の***量の増加が認められた。 As shown in Table 13, in the cadmium (Cd), 0.04 in average value (zg / hr) force, is increased et 0.067 711 and mercury (1¾) Similarly approximately 1.5 times the excretion was observed As shown in Table 13, the average excretion of lead (Pb) was 0.063 (zg / hr) and 0.092 (μg / hr), an increase of about 1.5 times.
アルミニウム(A1)においては、平均値では 0.117(〃§/}11 カ、ら0.417(μ8/}ιι·) と***量の増加が認められた。 For aluminum (A1), the mean value was 0.117 (〃 § /} 11, et al. 0.417 (μ 8 /} ιι ·), indicating an increase in excretion.
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)におレ、て有意差 (pく 0· 05)をもって、本発明の健 康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is examined in the same manner as arsenic, mercury (Hg), cadmium (Cd), lead (Pb), and aluminum (A1) have significant differences (p Increased excretion of harmful minerals in urine after ingestion of the healthy food of the invention was observed before ingestion.
[0058] 一方、尿中ミネラル***量では、表 14に示されるように、カルシウム(Ca)において 、平均値では 7.711 (/i g/hr)力ら 11.586 (/i g/hr)と増カロして約 1.5倍の変ィ匕 があったものの、この結果にヒ素同様の検定を行うと、 t検定において有意差は得られ ない結果となった。 [0058] On the other hand, as shown in Table 14, urinary mineral excretion increased in calcium (Ca) by an average of 7.711 (/ ig / hr) to 11.586 (/ ig / hr). About 1.5 times However, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p<0.05)は得られなかつ た。  Similarly, as a result of performing a test for changes in urine mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained.
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 8  Example 8
[0059] 実施例 8における健康食品の成分は、  [0059] The components of the health food in Example 8 were as follows:
メチルスルフォニルメタン(60) mg、クェン酸(100)mg、 L一シスチン(2· 5)mgに、リ ンゴ酸(100)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50) mg 、フィコシァニン(2.5)mg、フィチン酸(0)mg、 L一システィン(0)mg、 L一メチォニン (5)mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α—リポ酸(0)mg、フラボノイド化 合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さ らに、ヒ、、タミン Bl(3)mg、ヒ、、タミン B2(3)mg、ヒ、、タミン B6 (3)mg、ヒ、、タミン B12 (3) μ g、葉酸(20) zg、ダルコサミンが(10) mg、ノ二が(10) mg及び、呈味剤は、ピーチ 果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。  To methylsulfonylmethane (60) mg, citric acid (100) mg, L-cystine (2.5) mg, linoleic acid (100) mg, L-parin (50) mg, L-mouth isine (50) mg, L-isoleucine (50) mg, phycocyanin (2.5) mg, phytic acid (0) mg, L-cystine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, α —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added. ) mg, argentine, tamamine B2 (3) mg, argentine, tamamine B6 (3) mg, argentine, tamamine B12 (3) μg, folic acid (20) zg, darcosamine (10) mg, noni (10) mg and the flavoring agent consist of (50) mg of peach juice and (1500) mg of oligosaccharide.
検査結果:  Inspection results:
[0060] [表 15] [0060] [Table 15]
就寝中、 時間当たりの尿中有害ミネラル***量 ( gZhr.) Urinary harmful mineral excretion per hour during bedtime (gZhr.)
[0061] [0061]
Figure imgf000025_0002
Figure imgf000025_0002
[0062] 実施例 8について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 15に示されるように、ヒ素(As)では、平均値においても 10· 69(/ig/hr)力ら 20.2 4( と約1.9倍の***量の増加が認められた。また、この結果を有意差検定 すると t検定において p値 0.016 (pく 0.05)と有意な差をもって摂取後にヒ素*** 量の増加があることが証明された。同様に各有害ミネラルについても検討すると、表 1 5に示されるように、水銀(Hg)では、平均値では 0.107(
Figure imgf000025_0001
カら0.182(/ig /hr)と約 1.7倍の***量の増加が認められた。 表 15に示されるように、カドミウム(Cd)においては、平均値では 0.033(/ig/hr) 力 0.064( /1 §/ )と水銀0¾)同様に約1.9倍の***量の増加が認められた。 表 15に示されるように、鉛(Pb)においては、平均値では 0· 059(
Figure imgf000026_0001
カら0. 087 ( μ g/hr)と約 1.5倍の***量の増加が認められた。
[0062] For Example 8, the amount of harmful mineral excretion during bedtime before and after ingestion of health food was summarized. As shown in Table 15, the average value of arsenic (As) was 10 · 69 (/ ig / hr) An increase in excretion of about 20.24 (and about 1.9-fold was observed. In addition, a significant difference test showed that the t-test showed a significant difference in p-value of 0.016 (p-0.05) after ingestion of arsenic excretion. Similarly, when each harmful mineral was examined, as shown in Table 15, the average value of mercury (Hg) was 0.107 (
Figure imgf000025_0001
The mosquitoes were 0.182 (/ ig / hr), an increase of the excretion of about 1.7 times. As shown in Table 15, in cadmium (Cd), the excretion was increased by about 1.9 times as in the case of 0.033 (/ ig / hr) on average and 0.064 (/ 1 § /) on mercury (0¾). Was. As shown in Table 15, the average value of lead (Pb) is
Figure imgf000026_0001
The excretion was increased by about 1.5 times to 0.087 (μg / hr).
アルミニウム(A1)においては、表 15に示されるように、平均値では 0.242 (μ g/hr) 力、ら 0.358 ( μ g/hr)と***量の増加が認められた。  As shown in Table 15, the excretion of aluminum (A1) was increased by an average of 0.242 (μg / hr) and 0.358 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)におレ、て有意差 (pく 0.05)をもって、本発明の健 康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is tested in the same manner as for arsenic, mercury (Hg), cadmium (Cd), lead (Pb) and aluminum (A1) have a significant difference (p <0.05). Urinary mineral excretion was increased after ingestion of healthy foods than before.
[0063] 一方、尿中ミネラル総***量では、表 16に示されるように、カルシウム(Ca)におい て、平均値では 9.662 ( Z g/hr)力ら 11.825 ( g/hr)と増カロして約 1.2倍の変 ィ匕があったものの、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得 られない結果となった。 [0063] On the other hand, as shown in Table 16, the total urinary mineral excretion increased by 9.662 (Z g / hr) and 11.825 (g / hr) in average in calcium (Ca). However, when the same test was performed as in the case of arsenic, no significant difference was obtained in the t-test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p<0.05)は得られなかつ た。  Similarly, as a result of performing a test for changes in urine mineral excretion for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained.
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 9  Example 9
[0064] 実施例 9における健康食品の成分は、  [0064] The components of the health food in Example 9 were as follows:
メチルスルフォニルメタン(50) mg、クェン酸(100)mg、 L_シスチン(3)mgに、リン ゴ酸(50)mg、 L一パリン(50)mg、 L一口イシン(50)mg、 L一イソロイシン(50)mg、フ ィコシァニン(2.5)mg、フィチン酸(0)mg、 L一システィン(0)mg、 L一メチォニン(5) mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α—リポ酸(0)mg、フラボノイド化合 物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さら に、ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン B12(3) /i g 、葉酸(20) /ig、ダルコサミンが(10) mg、ノニカ S(0)mg及び、呈味剤は、オレンジ果 汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 To methylsulfonylmethane (50) mg, citric acid (100) mg, L_cystine (3) mg, malic acid (50) mg, L-parin (50) mg, L-bite isine (50) mg, L-cystine isoleucine (50) mg, off Ikoshianin (2.5) mg, phytic acid (0) mg, L one cysteine (0) mg, L one Mechionin (5) m g, Echirenjiamin (0) mg, EDTA (0 ) mg, α —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, and alginic acid (0) mg were added, and vitamin Bl (3) mg and vitamin B2 were added. (3) mg, vitamin B6 (3) mg, vitamin B12 (3) / ig, folic acid (20) / ig, dalcosamine (10) mg, nonica S (0) mg, and flavoring agent are orange fruits Juice (50) mg and oligosaccharide (1500) mg are added.
検査結果;  Inspection results;
[0065] [表 17] [0065] [Table 17]
表 17 就寝中、 時間当たりの尿中有害ミネラル***量 (AigZhr.)  Table 17 Urinary toxic mineral excretion per hour during bedtime (AigZhr.)
[0066] [0066]
Figure imgf000027_0001
Figure imgf000027_0001
実施例 9について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、表 17に示されるように、ヒ素(As)では、平均ィ直におレヽても 8. 708( zg/hr)力ら 16. 6 97( §/^)と約1. 9倍の***量の増加が認められた。また、この結果を有意差検 定すると t検定において有意な差をもって摂取後にヒ素***量の増加があることが証 明された。同様に各有害ミネラルについても検討すると、表 17に示されるように、水 銀(Hg)では、平均ィ直では 0. 088 §/1^)カら0. 139 ( §/1^)と約1. 6倍の ί非 泄量の増加が認められた。 For Example 9, the harmful mineral excretions at bedtime before and after ingesting the health food were summarized. As shown in Table 17, the arsenic (As) level of 8.708 (zg / hr) The amount of excretion increased by about 1.9 times, which was 16.697 ( § / ^). In addition, this result It was demonstrated that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test. Similarly, when examining each harmful mineral, as shown in Table 17, the average of mercury (Hg) was 0.088 § / 1 ^) and 0.139 (§ / 1 ^). 1. 6-fold increase in non-excretion was observed.
表 17に示されるように、カドミウム(Cd)においては、平均値では 0. 038 ( z g/hr) 力 0. 064 ( z g/hr)と水銀 (Hg)同様に約 1. 7倍の***量の増加が認められた。 表 17に示されるように、鉛(Pb)においては、平均値では 0. 149 ( z g/hrW 0. 179 ( μ g/hr)と約 1. 2倍の***量の増加が認められた。  As shown in Table 17, the average value of cadmium (Cd) is 0.038 (zg / hr), the power is 0.064 (zg / hr), and the amount of excretion is about 1.7 times that of mercury (Hg). Increased. As shown in Table 17, the average excretion of lead (Pb) was 0.149 (zg / hrW 0.179 (μg / hr)), an increase of about 1.2 times.
アルミニウム(A1)においては、表 17に示されるように、平均値では 0. 234 ( μ g/hr) 力、ら 0. 355 ( μ g/hr)と***量の増加が認められた。  In aluminum (A1), as shown in Table 17, the average value was 0.234 (μg / hr), the average was 0.355 (μg / hr), and an increase in excretion was observed.
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)におレ、ては有意差 (pく 0. 05)をもって、本発明の 健康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  When harmful mineral excretion is tested in the same way as arsenic, mercury (Hg), cadmium (Cd), lead (Pb), and aluminum (A1) have significant differences (p <0.05). An increase in urinary harmful mineral excretion after ingestion of the health food of the present invention was observed before ingestion.
[0068] 一方、尿中ミネラル***量では、表 18に示されるように、カルシウム(Ca)において 、平均値では 7· 281 g/hr)力ら 8. 833 ( g/hr)と増量して約 1. 2倍の変化が あったものの、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得られ ない結果となった。 [0068] On the other hand, as shown in Table 18, urinary mineral excretion was increased to 8.833 (g / hr) for calcium (Ca) at an average value of 7 · 281 g / hr. Although there was a change of about 1.2 times, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p< 0. 05)は得られなかつ た。  Similarly, a test was conducted for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo) for changes in urinary mineral excretion, and no significant difference (p <0.05) was obtained. .
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 10  Example 10
[0069] 実施例 10における健康食品の成分は、  [0069] The components of the health food in Example 10 were as follows:
メチルスルフォニルメタン(50) mg、クェン酸(50) mg、 L一シスチン(2· 5) mgに、リン ゴ酸(50) mg、 L一パリン(100) mg、 L一口イシン(100) mg、 L一イソロイシン(100) m g、フィコシァニン(2· 5) mg、フィチン酸(0) mg、 L—システィン(0) mg、 L一メチォ二 ン(5)mg、エチレンジァミン(0)mg、 EDTA(0)mg、 α_リポ酸(0)mg、フラボノイド 化合物(0)mg、酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、 さらに、ビタミン Bl(3)mg、ビタミン B2(3)mg、ビタミン B6(3)mg、ビタミン B12(3) g、葉酸(20) zg、ダルコサミンが(10) mg、ノニカ O) mg及び、呈味剤は、オレン ジ果汁が(50) mg、オリゴ糖が(1500) mg添加されて成る。 To methylsulfonylmethane (50) mg, citric acid (50) mg, L-cystine (2.5) mg, malic acid (50) mg, L-parin (100) mg, L-mouth isine (100) mg, L-isoleucine (100) mg, phycocyanin (2.5) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methioni (5) mg, ethylenediamine (0) mg, EDTA (0) mg, α_lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, alginic acid (0 ) mg, vitamin Bl (3) mg, vitamin B2 (3) mg, vitamin B6 (3) mg, vitamin B12 (3) g, folic acid (20) zg, dalcosamine (10) mg, nonica O) mg and the flavoring agent consist of (50) mg of orange juice and (1500) mg of oligosaccharide.
検査結果; Inspection results;
[表 19] 就寝中、 時間当たりの尿中有害ミネラル***量 (/ gZhr.) 男 摂前 摂後 摂前 摂後 摂前 摂後 摂前 摂前 摂後 性 A s A s Hg Hg Cd Cd A 1 A 1 P b P b[Table 19] Urinary harmful mineral excretion per hour during bedtime (/ gZhr.) Male Before feeding After feeding Before feeding After feeding After feeding Before feeding After feeding Sex As A s Hg Hg Cd Cd A 1 A 1 Pb P b
A 5.368 12.796 0.056 0.098 0.057 0.079 0.163 0.175 0.052 0.097A 5.368 12.796 0.056 0.098 0.057 0.079 0.163 0.175 0.052 0.097
B 9.826 18.767 0.097 0.321 0.018 0.082 0.263 0.610 0.028 0.072B 9.826 18.767 0.097 0.321 0.018 0.082 0.263 0.610 0.028 0.072
C 3.867 12.785 0.067 0.102 0.053 0.059 0.453 0.576 0.028 0.063C 3.867 12.785 0.067 0.102 0.053 0.059 0.453 0.576 0.028 0.063
D 15.116 28.239 0.038 0.195 0.026 0.043 0.313 0.289 0.057 0.124D 15.116 28.239 0.038 0.195 0.026 0.043 0.313 0.289 0.057 0.124
E 5.892 21.326 0.124 0.198 0.038 0.092 0.468 0.635 0.062 0.097E 5.892 21.326 0.124 0.198 0.038 0.092 0.468 0.635 0.062 0.097
F 30.496 39.337 0.077 0.192 0.083 0.071 0.282 0.263 0.026 0.073F 30.496 39.337 0.077 0.192 0.083 0.071 0.282 0.263 0.026 0.073
G 9.382 18.795 0.053 0.178 0.053 0.081 0.097 0.412 0.052 0.113G 9.382 18.795 0.053 0.178 0.053 0.081 0.097 0.412 0.052 0.113
H 1.563 3.829 0.112 0.198 0.043 0.072 1.032 1.282 0.143 0.138H 1.563 3.829 0.112 0.198 0.043 0.072 1.032 1.282 0.143 0.138
I 12.643 21.369 0.089 0.263 0.021 0.073 0.467 0.783 0.073 0.133I 12.643 21.369 0.089 0.263 0.021 0.073 0.467 0.783 0.073 0.133
Av 10.461 19.694 0.079 0.194 0.044 0.072 0.393 0.558 0.058 0.101 Av 10.461 19.694 0.079 0.194 0.044 0.072 0.393 0.558 0.058 0.101
[表 20] 表 20 就寝中、 時間当たりの尿中ミネラル***量 ( g/hr.) 男 摂前 摂後 摂前 摂後 摂前 摂後 摂前 摂後 摂前 摂後 性 C a C a Mg Mg Z n Z n Mn Mn Mo Mo[Table 20] Table 20 Urinary mineral excretion per hour during bedtime (g / hr.) Male Before feeding After feeding Before feeding After feeding After feeding After feeding After feeding Sex C a C a Mg Mg Z n Z n Mn Mn Mo Mo
A 5.039 5.382 6.881 7.356 28.41 26.32 0.011 0.005 2.738 2.335A 5.039 5.382 6.881 7.356 28.41 26.32 0.011 0.005 2.738 2.335
B 6.194 10.142 3.832 4.876 8.334 9.312 0.002 0 10.34 9.133B 6.194 10.142 3.832 4.876 8.334 9.312 0.002 0 10.34 9.133
C 9.832 10.167 1.218 4.372 12.67 13.15 0.061 0.112 3.528 5.783C 9.832 10.167 1.218 4.372 12.67 13.15 0.061 0.112 3.528 5.783
D 17.834 16.557 7.835 5.127 6.793 9.386 0.002 0 8.317 9.283D 17.834 16.557 7.835 5.127 6.793 9.386 0.002 0 8.317 9.283
E 6.289 10.377 4.438 10.38 22.73 24.56 0 0.002 5.829 3.762E 6.289 10.377 4.438 10.38 22.73 24.56 0 0.002 5.829 3.762
F 17.388 14.865 6.782 3.983 9.867 7.382 0.003 0.008 10.18 】1.33F 17.388 14.865 6.782 3.983 9.867 7.382 0.003 0.008 10.18】 1.33
G 2.339 5.082 5.338 8.467 4.563 7.112 0.016 0.023 7.386 9.183G 2.339 5.082 5.338 8.467 4.563 7.112 0.016 0.023 7.386 9.183
H 11.147 9.964 10.28 7.386 18.36 21.19 0 0.007 1.832 2.472H 11.147 9.964 10.28 7.386 18.36 21.19 0 0.007 1.832 2.472
I 7.339 7.834 4.397 5.137 12.66 14.39 0.021 0.012 5.396 7.138I 7.339 7.834 4.397 5.137 12.66 14.39 0.021 0.012 5.396 7.138
Av 9.267 10.041 5.667 6.343 13.82 14.76 0.013 0.019 6.172 6.713 [0072] 実施例 10について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、 表 19に示されるように、ヒ素(As)では、平均値においても 10. 54 ( /i g/hr)から 19 . 70 ( /1 §/1^)と約1. 9倍の***量の増加が認められた。また、この結果を有意差 検定すると t検定において有意な差をもって摂取後にヒ素***量の増加があることが 証明された。同様に各有害ミネラルについても検討すると、表 19に示されるように、 水銀(Hg)では、平均値では 0. 079 ( §/}^)カら0. 194 ( x g/hr)と約 2. 4倍の ***量の増加が認められた。 Av 9.267 10.041 5.667 6.343 13.82 14.76 0.013 0.019 6.172 6.713 [0072] For Example 10, the amount of harmful mineral excretion at bedtime before and after ingestion of health food was summarized. As shown in Table 19, the average value of arsenic (As) was 10.54 (/ ig / hr) The excretion was increased by about 1.9-fold to 19.70 (/ 1 § / 1 ^). In addition, a significant difference test of the results proved that there was a significant difference in the arsenic excretion after ingestion with a significant difference in the t-test. Similarly, when examining each harmful mineral, as shown in Table 19, the average value of mercury (Hg) is 0.079 ( § /} ^) and 0.194 (xg / hr), which is about 2.94. A four-fold increase in excretion was noted.
表 19に示されるように、カドミウム(Cd)においては、平均値では 0. 043 ( μ g/hr) 力 0. 072 ( z gZhr)と水銀 (Hg)同様に約 1. 6倍の***量の増加が認められた。 表 19に示されるように、鉛(Pb)においては、平均値では 0. 057 ( μ g/hr)力も 0. 101 ( μ g/hr)と約 1. 7倍の***量の増加が認められた。  As shown in Table 19, for cadmium (Cd), the average value is 0.043 (μg / hr), the power is 0.072 (z gZhr), and the amount of excretion is about 1.6 times that of mercury (Hg). Increased. As shown in Table 19, for lead (Pb), the average excretion was 0.057 (μg / hr) and the excretion was 0.17 (μg / hr). Was done.
アルミニウム(A1)においては、表 19に示されるように、平均値では 0. 393 ( μ g/hr) 力ら 0. 558 ( μ g/hr)と***量の増加が認められた。  For aluminum (A1), as shown in Table 19, the mean value was 0.393 (μg / hr), and 0.558 (μg / hr).
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)においては有意差 (ρ< 0· 05)をもって、本発明の 健康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  Assays of these harmful mineral excretions in the same manner as arsenic showed that the mercury (Hg), cadmium (Cd), lead (Pb) and aluminum (A1) had a significant difference (ρ <0.05), An increase in urinary harmful mineral excretion after ingestion was observed before ingestion of food.
[0073] 一方、尿中ミネラル***量では、表 20に示されるように、カルシウム(Ca)において 、平均値では 9· 267 ( /i g/hr)力ら 10. 041 ( /i g/hr)と増カロして約 1. 1倍の変化 があったものの、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得ら れない結果となった。 [0073] On the other hand, as shown in Table 20, urinary mineral excretion shows that calcium (Ca) has an average of 9.267 (/ ig / hr) and 10.041 (/ ig / hr). Although the increase in calories resulted in a change of about 1.1-fold, when a test similar to arsenic was performed on this result, no significant difference was obtained in the t-test.
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)も同様に尿中ミ ネラル***量変化について、検定を行った結果有意差 (p< 0. 05)は得られなかつ た。  Similarly, as for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo), no significant difference (p <0.05) was obtained as a result of testing for changes in urinary mineral excretion. .
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、これは 二次的に健康の維持、増進に役立つ食品と考えられる。  The urinary excretion of harmful minerals increases when the health food of the present invention is ingested and not consumed in daily life when it is ingested with a statistically significant difference. It is considered to be a food that helps maintain and improve food quality.
実施例 11  Example 11
[0074] 実施例 11における健康食品の成分は、 メチルスルフォニルメタン(50) mg、クェン酸(45)mg、 L一シスチン(5)mgに、リンゴ 酸(0)mg、 L_パリン(0)mg、 L一口イシン(0)mg、 L一イソロイシン(0)mg、フィコシァ ニン(0)mg、フィチン酸(0)mg、 L—システィン(0)mg、 L一メチォニン(5)mg、ェチ レンジァミン(0)mg、 EDTA(0)mg、 ひ—リポ酸(0)mg、フラボノイド化合物(0)mg、 酒石酸(0)mg、ダルコン酸(0)mg、アルギン酸(0)mgが加えられ、さらに、ビタミン B l(10)mg、ビタミン B2(10)mg、ビタミン B6 (10)mg、ビタミン B12 (5) μ g、葉酸(2 5) zg、グノレコサミンが(0)mg、ノ二が(0)mg添加されて成る。 [0074] The components of the health food in Example 11 were: Methylsulfonylmethane (50) mg, citric acid (45) mg, L-cystine (5) mg, malic acid (0) mg, L_palin (0) mg, L-mouth isine (0) mg, L-isoleucine (0) mg, phycocyanin (0) mg, phytic acid (0) mg, L-cysteine (0) mg, L-methionine (5) mg, ethylenediamine (0) mg, EDTA (0) mg, —Lipoic acid (0) mg, flavonoid compound (0) mg, tartaric acid (0) mg, dalconic acid (0) mg, alginic acid (0) mg, vitamin B l (10) mg, vitamin B2 ( 10) mg, vitamin B6 (10) mg, vitamin B12 (5) μg, folic acid (25) zg, (0) mg gnorecosamine, and (0) mg noni.
検査結果; Inspection results;
[表 21] [Table 21]
就寝中、 時間当たりの尿中有害ミネラル***量 gZhr.)  Urinary toxic mineral excretion per hour during bedtime gZhr.)
Figure imgf000031_0001
Figure imgf000031_0001
[表 22] [Table 22]
就寝中、 時間当たりの尿中ミネラル***量 ( gZhr. ) Urinary mineral excretion per hour during bedtime (gZhr.)
Figure imgf000032_0002
Figure imgf000032_0002
[0077] 実施例 11について、健康食品摂取前後の就寝中有害ミネラル***量をまとめると、 表 21に示されるように、ヒ素(As)では、平均値においても 9. 31 ( z g/hr)から 11. 90 ( §/}11 と約1. 3倍の***量の増加が認められた。また、この結果を有意差検 定すると t検定において (pく 0. 05)、有意な差をもって摂取後にヒ素***量の増加 力あることが証明された。同様に各有害ミネラルについても検討すると、表 21に示さ れるように、水銀(Hg)では、
Figure imgf000032_0001
と 約 1. 3倍の***量の増加が認められた。
[0077] For Example 11, the harmful mineral excretions at bedtime before and after ingestion of the health food were summarized. As shown in Table 21, the average value of arsenic (As) was 9.31 (zg / hr). The excretion increased by about 1.3-fold from 11.90 ( § /} 11, and a significant difference test was performed. The t-test (p <0.05) showed a significant difference in the intake. It was later proved to be capable of increasing arsenic excretion.Similarly, when each harmful mineral was examined, as shown in Table 21, mercury (Hg)
Figure imgf000032_0001
And an increase in excretion of about 1.3 times was observed.
表 21に示されるように、カドミウム(Cd)においては、平均値では 0. 043 ( μ g/hr) 力 0. 064 ( μ g/hr)と水銀 (Hg)同様に約 1. 5倍の***量の増加が認められた。 表 21に示されるように、鉛(Pb)においては、平均値では 0· 073 g/hr)力も 0. 092 ( μ g/hr)と約 1 · 3倍の***量の増加が認められた。  As shown in Table 21, the average value of cadmium (Cd) is 0.043 (μg / hr) and the power is 0.064 (μg / hr), which is about 1.5 times higher than that of mercury (Hg). Increased excretion was observed. As shown in Table 21, for lead (Pb), the average excretion was 0.073 g / hr, and the excretion was about 1.3 times as high as 0.092 (μg / hr). .
アルミニウム(A1)においては、表 21に示されるように、平均値では 0· 548 ( β g/hr) 力ら 0. 71 l ( /i g/hr)と***量の増加が認められた。 In aluminum (A1), as shown in Table 21, the average value increase of 0 · 548 (β g / hr ) Power et 0. 71 l (/ ig / hr ) and excretion were observed.
これら有害ミネラル***量についてヒ素同様の検定を行うと、水銀 (Hg)、カドミウム (Cd)、鉛(Pb)、アルミニウム (A1)においては有意差 (ρ< 0· 05)をもって、本発明の 健康食品摂取前より摂取後の尿中有害ミネラル***量の増加が認められた。  Assays of these harmful mineral excretions in the same manner as arsenic showed that the mercury (Hg), cadmium (Cd), lead (Pb) and aluminum (A1) had a significant difference (ρ <0.05), An increase in urinary harmful mineral excretion after ingestion was observed before ingestion of food.
[0078] 一方、尿中ミネラル***量では、表 22に示されるように、カルシウム(Ca)において 、平均値では 9. 019 ( /i g/hr)力ら 9. 443 ( /i g/hr)と増カロして約 1. 04倍の変ィ匕 があったものの、この結果にヒ素同様の検定を行うと、 t検定において、有意差は得ら れなレヽ結果となった。 (t検定、 ρ< 0· 05で 0. 111) [0078] On the other hand, as shown in Table 22, the urinary mineral excretion amount was 9.019 (/ ig / hr) and 9.443 (/ ig / hr) in average for calcium (Ca). Increase the number of calories by about 1.04 times However, when a test similar to arsenic was performed on this result, a significant difference was not obtained in the t test. (T-test, ρ <0. 05 for 0.11)
マグネシウム(Mg)、亜鉛(Zn)、マンガン(Mn)、モリブデン(Mo)にも同様に尿中 ミネラル***量変化について、検定を行った結果有意差 (p< 0. 05)は得られなかつ た。  Similarly, a test was conducted for magnesium (Mg), zinc (Zn), manganese (Mn), and molybdenum (Mo) for changes in urinary mineral excretion, and no significant difference (p <0.05) was obtained. .
日常生活で本発明の健康食品を摂取した場合と摂取しなかった場合では、統計学 的有意差をもって摂取した場合の方が有害ミネラルの尿中***量が増加し、二次的 に健康の維持、増進に役立つ食品と考えられる。  Intake of the health food of the present invention in daily life and in the absence of the health food increase the urinary excretion of harmful minerals with a statistically significant difference and maintain secondary health. It is considered to be a useful food for promotion.
産業上の利用可能性  Industrial applicability
[0079] 食品や食品添加物等により人体又は動物の体内に蓄積、沈着されて様々な健康障 害、疾病を誘発する有害重金属又は有害ミネラルを人体又は動物の体内から効率 的に***させて、健康障害、疾病の誘発を未然に防止する。さらに改善、治癒を必 要とする分野にも広く利用することが可能である。 [0079] Harmful heavy metals or harmful minerals that accumulate and deposit in the human body or animal body by foods and food additives and induce various health disorders and diseases are efficiently excreted from the human body or animal body, Prevent the induction of health disorders and diseases. Furthermore, it can be widely used in fields that require improvement and healing.
図面の簡単な説明  Brief Description of Drawings
[0080] [図 1]健康食品摂取前後の尿中鉛 (Pb)総***量の比較グラフである。  FIG. 1 is a comparison graph of total urinary lead (Pb) excretion before and after ingestion of health food.
[図 2]健康食品摂取前後の尿中ヒ素 (As)総***量の比較グラフである。  FIG. 2 is a comparison graph of total urinary arsenic (As) excretion before and after ingestion of health food.
[図 3]健康食品摂取前後の尿中水銀 (Hg)総***量の比較グラフである。  FIG. 3 is a comparison graph of total urinary mercury (Hg) excretion before and after intake of health food.
[図 4]健康食品摂取前後の尿中カドミウム (Cd)総***量の比較グラフである。  FIG. 4 is a comparison graph of the total excretion of cadmium (Cd) in urine before and after intake of health food.

Claims

請求の範囲 The scope of the claims
[1] 必須キレート剤又はキレート剤誘導材料物質であるメチルスルフォニルメタン、クェン 酸、 L一シスチンから成り、  [1] Consists of essential chelating agent or chelating agent-derived material methylsulfonylmethane, citric acid, L-cystine,
前記必須キレート剤又はキレート剤誘導材料物質は固体状又は流体状に形成され、 前記必須キレート剤又はキレート剤誘導材料物質が人体又は動物の体内に摂取さ れることにより、前記人体又は動物の体内の有害重金属又は有害ミネラルを封鎖して 前記有害重金属のキレートイヒ合物又は前記有害ミネラルのキレートィヒ合物が形成さ れ、前記有害重金属又は前記有害ミネラルが前記人体又は動物の体内から***さ れることを特徴とする健康食品。  The essential chelating agent or the chelating agent-derived material is formed in a solid state or a fluid state, and the essential chelating agent or the chelating agent-derived material is ingested into a human body or an animal body, whereby the human body or the animal body has The harmful heavy metal or harmful mineral is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or the harmful mineral is excreted from the human or animal body. And health food.
[2] リンゴ酸、 L—バリン、 L—ロイシン、 L一イソロイシン、フィコシァニン、フィチン酸、 L—シ スティン、 L—メチォニン、エチレンジァミン、 EDTA、 α—リポ酸、フラボノイド化合物、 酒石酸、グノレコン酸、アルギン酸の内、少なくとも一種類以上から成る添加キレート剤 が添加され、前記添加キレート剤は固体状又は流体状に形成され、前記添加キレー ト剤が人体又は動物の体内に摂取されることにより、前記人体又は動物の体内の有 害重金属又は有害ミネラルを封鎖して前記有害重金属のキレート化合物又は前記 有害ミネラルのキレートィヒ合物が形成され、前記有害重金属又は前記有害ミネラル が前記人体又は動物の体内から***される請求項 1記載の健康食品。 [2] malic acid, L-valine, L-leucine, L-isoleucine, phycocyanin, phytic acid, L-cysteine, L-methionine, ethylenediamine, EDTA, α-lipoic acid, flavonoid compounds, tartaric acid, gnoreconic acid, alginic acid Among the above, an added chelating agent comprising at least one or more is added, and the added chelating agent is formed in a solid or fluid state. Alternatively, the harmful heavy metal or harmful mineral in the animal body is blocked to form the harmful heavy metal chelate compound or the harmful mineral chelate compound, and the harmful heavy metal or the harmful mineral is excreted from the human or animal body. The health food according to claim 1.
[3] 前記必須キレート剤又はキレート剤誘導材料物質、及び前記添加キレート剤が、 0.  [3] The essential chelating agent or the chelating agent-derived material, and the added chelating agent,
001— 35. 0重量%である請求項 2記載の健康食品。  The health food according to claim 2, wherein the content is from 001 to 35.0% by weight.
[4] ビタミン、糖質のいずれか一種以上が添加される請求項 1又は 2記載の健康食品。  [4] The health food according to claim 1 or 2, wherein at least one of vitamins and carbohydrates is added.
[5] 前記ビタミンは、ビタミン Bl、ビタミン Β2、ビタミン Β6、ビタミン Β12、葉酸のいずれか 一種類以上より成り、前記糖質は、グノレコサミンである請求項 4記載の健康食品。  5. The health food according to claim 4, wherein the vitamin is at least one of vitamin Bl, vitamin Β2, vitamin Β6, vitamin Β12, and folic acid, and the saccharide is gnorecosamine.
[6] ノ二が添加される請求項 1又は 2記載の健康食品。  [6] The health food according to claim 1 or 2, to which Noji is added.
[7] パウダー、顆粒、錠剤、又はペーストに形成され、或いは前記パウダー、前記顆粒が カプセルに収容される請求項 1又は 2記載の健康食品。  [7] The health food according to claim 1 or 2, wherein the health food is formed into powder, granules, tablets, or pastes, or the powder or granules are contained in a capsule.
[8] 呈味剤として、果汁エキスであるボンタンエキス、ライチェキス、リンゴ果汁、オレンジ 果汁、ゆずエキス、ピーチフレーバー、ウメフレーバー、甘味剤であるアセスルファム[8] As flavoring agents, fruit juice extracts such as Bontang extract, lychekis, apple juice, orange juice, citron extract, peach flavor, ume flavor, and sweetener Acesulfame
Κ、エリスリトール、オリゴ糖類、マンノース、キシリトール、異性化糖類、茶成分である 緑茶、ウーロン茶、バナバ茶、杜仲茶、鉄観音茶、ノ、トムギ茶、アマチヤヅル茶、マコ モ茶、昆布茶、及び、ヨーグルトフレーバー、ビタミン Cのいずれか一種類以上が添 加される請求項 1又は 2記載の健康食品。 Κ, erythritol, oligosaccharides, mannose, xylitol, isomerized saccharides, tea components Green tea, oolong tea, banaba tea, Tochu tea, Tetsu Kannon tea, Nori, Barley tea, Amachiadul tea, Macomo tea, Kelp tea, yogurt flavor, and at least one of vitamin C is added. Or the health food described in 2.
前記有害重金属は Cd、 Hg、 Pb、 Crのいずれか一種類以上から成り、前記有害ミネ ラノレは Al、 Be、 Asのいずれか一種類以上から成る請求項 1又は 2記載の健康食品。 3. The health food according to claim 1, wherein the harmful heavy metal is composed of at least one of Cd, Hg, Pb, and Cr, and the harmful mineral is composed of at least one of Al, Be, and As.
PCT/JP2004/006849 2004-05-20 2004-05-20 Health food WO2005112667A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2004/006849 WO2005112667A1 (en) 2004-05-20 2004-05-20 Health food
JP2006519161A JPWO2005112667A1 (en) 2004-05-20 2004-05-20 healthy food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2004/006849 WO2005112667A1 (en) 2004-05-20 2004-05-20 Health food

Publications (1)

Publication Number Publication Date
WO2005112667A1 true WO2005112667A1 (en) 2005-12-01

Family

ID=35428205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/006849 WO2005112667A1 (en) 2004-05-20 2004-05-20 Health food

Country Status (2)

Country Link
JP (1) JPWO2005112667A1 (en)
WO (1) WO2005112667A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006111566A (en) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd Methionine-blended internal use liquid agent
JP2007197413A (en) * 2006-01-28 2007-08-09 Bhn Kk Pigmentation inhibitor and its utilization
JP2007262054A (en) * 2006-03-02 2007-10-11 Taisho Pharmaceut Co Ltd Liquid preparation for oral administration
JP2011512366A (en) * 2008-02-20 2011-04-21 グノーシス・エツセ・ピー・アー Folate, their composition and use
JP2012219013A (en) * 2011-04-04 2012-11-12 Nihon Medi Physics Co Ltd Composition for controlling transporting capacity of kidney transporter
CN102972752A (en) * 2012-08-21 2013-03-20 苏州谷力生物科技有限公司 Composition having heavy metal removing function
CN105769843A (en) * 2016-04-08 2016-07-20 南京师范大学 Application of L-theanine in preparation of medicine for preventing or treating body injuries caused by heavy metal cadmium
CN106232143A (en) * 2014-04-02 2016-12-14 巴利阿里群岛大学 Urinary acidifier and the combination preparation of crystallization inhibitor and it is for treating or prevent the application of the renal calculus of phosphate or calcium phosphate induction
KR20180058251A (en) * 2016-11-23 2018-06-01 충남태안영농조합법인 Functional food composition for maintenance of mineral balance in body and detoxification heavy metal using grub
CN108348777A (en) * 2015-09-30 2018-07-31 诺瓦利克有限责任公司 Semi-fluorinated compound and its composition
KR101957502B1 (en) * 2018-08-17 2019-03-12 이승훈 Composition for preventing or improving obsity, fatty liver and diabetes comprising Methyl Sulfonyl Methane: Dimethyl Sulfone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59501748A (en) * 1982-09-14 1984-10-18 ハ−シユラ−,ロバ−ト ジエイ Pharmaceutical uses of methylsulfonium methane and compositions containing it
JPS6212A (en) * 1985-04-29 1987-01-06 ロバ−ト、ジエイ、ハ−シユラ− Bait product containing methylsulfonylmethane and use
JP2002080385A (en) * 2000-06-27 2002-03-19 Hayashibara Biochem Lab Inc Metal deposition inhibitor
JP2003535126A (en) * 2000-06-02 2003-11-25 ザ プロクター アンド ギャンブル カンパニー Compositions, kits and methods for promoting defined health benefits

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59501748A (en) * 1982-09-14 1984-10-18 ハ−シユラ−,ロバ−ト ジエイ Pharmaceutical uses of methylsulfonium methane and compositions containing it
JPS6212A (en) * 1985-04-29 1987-01-06 ロバ−ト、ジエイ、ハ−シユラ− Bait product containing methylsulfonylmethane and use
JP2003535126A (en) * 2000-06-02 2003-11-25 ザ プロクター アンド ギャンブル カンパニー Compositions, kits and methods for promoting defined health benefits
JP2002080385A (en) * 2000-06-27 2002-03-19 Hayashibara Biochem Lab Inc Metal deposition inhibitor

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006111566A (en) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd Methionine-blended internal use liquid agent
JP2007197413A (en) * 2006-01-28 2007-08-09 Bhn Kk Pigmentation inhibitor and its utilization
JP2007262054A (en) * 2006-03-02 2007-10-11 Taisho Pharmaceut Co Ltd Liquid preparation for oral administration
JP2011512366A (en) * 2008-02-20 2011-04-21 グノーシス・エツセ・ピー・アー Folate, their composition and use
JP2012219013A (en) * 2011-04-04 2012-11-12 Nihon Medi Physics Co Ltd Composition for controlling transporting capacity of kidney transporter
CN102972752A (en) * 2012-08-21 2013-03-20 苏州谷力生物科技有限公司 Composition having heavy metal removing function
CN106232143A (en) * 2014-04-02 2016-12-14 巴利阿里群岛大学 Urinary acidifier and the combination preparation of crystallization inhibitor and it is for treating or prevent the application of the renal calculus of phosphate or calcium phosphate induction
US20170106032A1 (en) * 2014-04-02 2017-04-20 Universitat De Les Illes Balears Combination of a urinary acidifier and a calcium phosphate crystallisation inhibitor for the treatment or prevention of renal lithiasis
CN108348777A (en) * 2015-09-30 2018-07-31 诺瓦利克有限责任公司 Semi-fluorinated compound and its composition
CN108348777B (en) * 2015-09-30 2020-04-28 诺瓦利克有限责任公司 Semifluorinated compounds and compositions thereof
CN105769843A (en) * 2016-04-08 2016-07-20 南京师范大学 Application of L-theanine in preparation of medicine for preventing or treating body injuries caused by heavy metal cadmium
KR20180058251A (en) * 2016-11-23 2018-06-01 충남태안영농조합법인 Functional food composition for maintenance of mineral balance in body and detoxification heavy metal using grub
KR101957502B1 (en) * 2018-08-17 2019-03-12 이승훈 Composition for preventing or improving obsity, fatty liver and diabetes comprising Methyl Sulfonyl Methane: Dimethyl Sulfone
WO2020036257A1 (en) * 2018-08-17 2020-02-20 이승훈 Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes
JP2021535121A (en) * 2018-08-17 2021-12-16 リー, スン フンLEE, Seung Hoon Composition for preventing or ameliorating obesity, fatty liver and diabetes containing methylsulfonylmethane

Also Published As

Publication number Publication date
JPWO2005112667A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
Walker et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study
Antoine et al. Dietary intake of minerals and trace elements in rice on the Jamaican market
Korfali et al. Evaluation of heavy metals content in dietary supplements in Lebanon
de Souza et al. Determination of total concentration and bioaccessible fraction of metals in infant cereals by MIP OES
Avula et al. Inorganic elemental compositions of commercial multivitamin/mineral dietary supplements: Application of collision/reaction cell inductively coupled-mass spectroscopy
Domingo et al. Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals
Javad et al. Analysis of aluminum, minerals and trace elements in the milk samples from lactating mothers in Hamadan, Iran
WO2005112667A1 (en) Health food
Marrero et al. Inductively coupled plasma optical emission spectrometric determination of fifteen elements in dietary supplements: are the concentrations declared in the labels accurate?
EP2271367B1 (en) Mineral absorption accelerator and iron deficiency anemia improver or food composition
CN102150854B (en) Health food with auxiliary protection function to chemical liver injury
Shams Tabrez et al. Microbial biofertilizers and micronutrient availability: the role of zinc in agriculture and human health
KR101171068B1 (en) Pharmaceutical Compositions for Diabetes Improvement and Prevention Containing Mineral Compositions as Effective Component
de OG Mendonça et al. Effects of an oxalate load on urinary oxalate excretion in calcium stone formers
Erdemir et al. Correlation of lithium bioaccessibility from tea (Camellia sinensis L.) with tea type and consumption habits
Arvanitidou et al. Serum copper and zinc concentrations in healthy children aged 3–14 years in Greece
Demir et al. Estimated daily intake and health risk assessment of toxic elements in infant formulas
Oloyede et al. Elemental composition of marketed milk from Nigeria and Brazil using ICP-OES: Health risk assessment study
Wojcieszek et al. Study of bioaccessibility of cobalt species in berries and seeds by mass spectrometry techniques
JP2003189818A (en) Functional food containing powdery sea-squirt
MacDonald et al. Long-term compliance with a novel vitamin and mineral supplement in older people with PKU
WO2019146790A1 (en) Food composition for ameliorating or preventing lifestyle-related diseases
Akter et al. Physio-biochemical changes in goats due to arsenic induced toxicity
Kolawole et al. Relationship between soil contents and plasma levels of selenium, chromium and manganese in healthy adult Nigerians
Taylor et al. Atomic spectrometry update. Clinical and biological materials, foods and beverages

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006519161

Country of ref document: JP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase